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ABSTRACT
Acute myeloid leukemia (AML) is associated with mutations or chromosomal transloca-
tions in genes encoding transcription factors. PU.1 is a transcription factor that is required 
for the development of nearly all white blood cell types of the immune system, including B 
cells, granulocytes, and monocytes. Mutation of the gene encoding PU.1, SPI1 in humans 
and Sfpi1 in mice, is associated with AML. We hypothesized that reduced expression of 
PU.1 in Sfpi1BN/BN myeloid cells will result in the development of AML in transplanted 
mice due to reduced repression of E2F1, leading to deregulation of the cell cycle. Results 
indicate that NOD/SCID/γc-/- mice transplanted with Sfpi1BN/BN splenocytes become sick 
with disease resembling AML. Induction of PU.1 expression results in repression of the 
cell cycle regulator, E2F1, suggesting PU.1 represses E2F1 in order to enable cell cycle 
exit and differentiation. Understanding the pathways controlled by PU.1 can be used in 
therapies for the treatment of AML. 
Keywords: PU.1, AML, transcription factor, myeloid cell, cell cycle, E2F1
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CHAPTER 1: INTRODUCTION
1.1 Acute Myeloid Leukemia (AML)
Acute myeloid leukemia (AML) is a cancer of the myeloid lineage of white blood 
cells. It is a disease characterized by a block in differentiation of myeloid cells and their 
uncontrolled proliferation in the bone marrow (1). The projected number of new diagno-
ses of AML in the United States in 2012 was nearly 14, 000, up from 12, 000 in 2010 (2). 
The estimated number of deaths from these diagnoses was 10, 200, surpassing the num-
ber of deaths in 2010 by over 2000 (2). Until the 1970s, five-year survival rates for AML 
were less than 15% (1). During the 1980s and 1990s refinements in the diagnosis and ad-
vances in therapeutic approaches improved the prognosis for patients with AML. None-
theless, the survival rate among patients less than 65 years of age is still only 40% (1) and 
the prospects for elderly AML patients is significantly worse, with median survival times 
of only a few months (3).  The dismal outlook for older patients is a result of not only 
the deteriorating health of the patient but also the nature of the disease (4). When taken 
with the fact that AML is the most common acute leukemia affecting adults (4), these 
discouraging statistics highlight the importance of study of the disease. AML is diagnosed 
by identification of leukemic myeloblasts in bone marrow exceeding 30% of marrow 
aspirate (1). Recently, the relevance in classifying the subtype of AML and determin-
ing course of treatment based on the specific subtype has become appreciated (1, 5). The 
most commonly used method of classification (known as the FAB classification system) 
divides AML into nine distinct subtypes based on the particular myeloid lineage involved 
and the degree of differentiation of the cells (1). These distinctions are determined by the 
morphological appearance of the blasts and their reactivity with histochemical stains (1). 
The FAB classification system was named after the group that developed it, the French-
American-British (FAB) group, and is listed in Table 1.1.  The FAB classification system 
also incorporates genetic trends, such as chromosomal rearrangements involving certain 
genes that are present in a large percentage of AML patients (1). Specifically, genes that 
1
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Table 1.1 FAB Classification of AML and associated genetic abnormalities/transcription factor mutations. 
Table 1.1 adapted from Lowenberg et al. 1999 (1) and Rosenbauer & Tenen 2007 (6) 
 
Results of Staining 
 
FAB  
Subtype 
Common Name 
(% of Cases) 
M SB NSE 
Transcription Factor 
(Frequency in AML) 
Mutations and Effects 
M0 Acute myeloblastic leukemia 
with minimal differentiation 
(3%)  
 
- - - RUNX1 (9%) 
 
EVI1 inv(3q26) and t(3;3) 
PU.1 (<7%) 
Missense, nonsense or 
frameshift mutations 
M1 Acute myeloblastic leukemia  
without maturation (15–20%)  
 
+ + - C/EBPα (7-9%) Amino-terminal 
dominant negative; 
carboxy-terminal loss of 
DNA binding 
M2 Acute myeloblastic leukemia 
with maturation (25–30%)  
 
+ + - RUNX1-ETO t(8;21) (12-15%) 
 
 
 
DEK-CAN t(6;9)  
C/EBPα (7-9%) 
RUNX1 DNA-binding 
domain fused to the 
transcriptional 
corepressor ETO 
 
Amino-terminal 
dominant negative; 
carboxy-terminal loss of 
DNA binding 
M3 Acute promyelocytic leukemia  
(5–10%)  
 
+ + - PML-RARα t(15;17) (6-7%) 
 
PLZF-RARα t(11;17) 
NPM-RARα t(5;17) 
 
PML gene fused to 
RARA 
M4 Acute myelomonocytic leukemia  
(20%) 
+ + + MLL fusions t11q23 (4-7%) 
 
 
 
MLL gene fused with 
one of 30 distinct genes 
encoding partner 
proteins 
 
DEK-CAN t(6;9) 
EVI1 inv(3q26) and t(3;3)  
PU.1 (<7%) 
C/EBPα (7-9%) 
 
 
 
 
Amino-terminal 
dominant negative; 
carboxy-terminal loss of 
DNA binding 
M4EO Acute myelomonocytic leukemia 
with abnormal eosinophils  
(5–10%) 
 
+ + + CBFβ-MYH11 inv16 
(8-10%) 
 
 
CBFβ-MYH11 t(16;16) 
 
Inversion of breaks in 
chromosome 16; joins 
CBFβ with the myosin 
gene MYH11 
M5 Acute monocytic leukemia   
(2–9%)  
 
- - + MLL fusions t11q23 (4-7%) 
MOZ-CBP t(8;16)  
PU.1 (<7%) 
 
M6 Erythroleukemia (3–5%) + + - PU.1 (<7%)  
M7 Acute megakaryocytic leukemia 
(3–12%)  
 
- - + t(1;22)   
M7 with 
Down’s 
syndrome 
    GATA1 (Nearly 100% in 
AMKL associated with 
Down’s syndrome) 
Amino-terminal 
dominant negative 
*AMKL, acute megakaryoblastic leukemia; CBFβ, core-binding factor- β; C/EBPα, CCAAT/enhancer binding protein-α; GATA1, GATA-
binding protein 1; MLL, mixed lineage leukemia; MYH11, myosin heavy chain 11; PML, promyelocytic leukemia; RARα, retinoic acid 
receptor-alpha; RUNX1, runt-related transcription factor 1 
encode DNA-binding transcription factors or the regulatory components of transcriptional 
complexes are frequently subject to mutation (1). For example, the t(8;21) translocation 
of the transcription factor acute myeloid leukemia 1 protein (AML1) (also known as runt-
related transcription factor 1, RUNX1 or core-binding factor subunit alpha-2, CBFα2), 
which regulates a number of hematopoiesis specific genes (1), is found in 12-15% of 
AML cases (6). The consequence of this chromosomal translocation is AML1 fusing to 
the transcriptional corepressor ETO. The resultant chimeric protein, represses instead of 
activating AML1-regulated target genes, including the genes encoding the transcription 
factors Purine-Rich Box Binding (PU.1), CCAAT/enhancer binding protein alpha (C/
EBPα) and RUNX1 (6). Interestingly, mutation of AML1’s normal partner, core binding 
factor-β (CBFβ) is associated with a different subtype of AML that involves chromosome 
16 inversions (6-7). This transcription factor mutation is present in 8-10% of AML cases 
(6). Examples of genetic mutations associated with the various FAB system subtypes of 
AML are included in Table 1.1. Due to the fact that transcription factors are essential for 
normal development of the hematopoietic system (6), it is not surprising that mutation 
results in deregulation of hematopoiesis (1,6), and ultimately, in some cases, cancer. The 
more recent World Health Organization (WHO) classification takes into account such 
leukemia-associated molecular parameters (6). 
Due to the important role that deregulated transcription factor activity can play in 
leukemia, such genes are currently being targeted for therapeutic intervention in my-
eloid and other cancers (6). For example, in acute promyelocytic leukemia (APL; FAB 
system subtype M3) a chromosomal translocation (t(15;17)) joins the gene encoding the 
transcription factor promyelocytic leukemia (PML) to the gene encoding retinoic acid 
receptor-α (RARα) (6, 8). It is well known that RARs play a role in the differentiation 
of myeloid cells (9); Tsai and Collins have demonstrated that inhibition of RARα blocks 
granulocytic differentiation (10). It has been shown that the PML- RARα fusion blocks 
myeloid transcription factors, such as PU.1 and C/EBPα, resulting in a block in myeloid 
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differentiation (6). The differentiation block can be relieved by treatment with all-trans 
retinoic acid (ATRA), increasing the survival of patients with APL (6, 11). Given that the 
hallmark of AML is a severe block in hematopoiesis, specifically myeloid differentiation 
(6), understanding normal hematopoiesis and myeloid development is critical. 
1.2 Hematopoiesis 
Hematopoiesis is the development of all blood lineages from a hematopoietic 
stem cell (HSC). HSCs exist as a small, rare population of cells in the bone marrow of 
adult mammals (12). HSCs are derived from the mesodermal layer of the embryo, which 
becomes specialized to a hematopoietic fate (12). Hematopoiesis, then, occurs in two 
major waves, at four sequential locations, in mammals: 1) the yolk sac, 2) an area sur-
rounding the dorsal aorta known as the aorta-gonad mesonephros (AGM) region, 3) the 
fetal liver, 4) the bone marrow (13). The placenta has been acknowledged as an additional 
site for hematopoiesis, during the AGM to fetal liver period (13). In the mouse, the first 
or “primitive” wave of blood production in the mammalian yolk sac yields red blood cells 
(erythroid cells) that enable tissue oxygenation as the embryo grows (13). The primitive 
wave begins at embryonic day 7.5 in the blood islands of the yolk sac and shortly after (~ 
embryonic day 8.5) in the AGM region. The AGM region produces hematopoietic pro-
genitor cells. The primitive hematopoietic system is rapidly replaced by adult-type hema-
topoiesis, known as “definitive” hematopoiesis, that begins at ~ embryonic day 10 (13). 
This second wave, in the mouse, involves the fetal liver, thymus, spleen, and ultimately 
the bone marrow; the second wave generates blood cells of specific lineages, such as B 
cells and T cells (13). Definitive hematopoiesis occurs first in the fetal liver, with maxi-
mal hematopoietic activity occurring embryonic day 14.5. Following embryonic day 15, 
hematopoiesis decreases in the fetal liver, presumably as hematopoiesis begins to occur 
in other immune organs such as the bone marrow and spleen (14). By embryonic day 20, 
hematopoiesis is underway in the bone marrow where it will occur for the remainder of 
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the animal’s life (14). As indicated, the developmental time periods for hematopoiesis 
mentioned, are for that of mice. Notably, there are differences between humans and mice, 
but the mouse model provides foundational information for understanding the develop-
ment of the hematopoietic system (15). 
The hematopoietic stem cell has two defining characteristics: self-renewal and 
multipotency (16). Self-renewal is the ability to undergo many cellular divisions while 
remaining undifferentiated. This includes the option of dividing asymmetrically, which 
allows one daughter cell to maintain the HSC population while allowing the second 
daughter cell to differentiate. Multipotency is the ability to differentiate into cell types of 
multiple different lineages. The HSC has the ability to generate progenitors, which dif-
ferentiate into all lineages of the blood in a hierarchal fashion (17). Multipotent stem cells 
go on to divide to produce a common lymphoid progenitor which gives rise to the lym-
phoid lineage, or a common myeloid progenitor which gives rise to the myeloid lineage. 
Terminally differentiated cell types of the lymphoid lineage include natural killer (NK) 
cells and the T and B lymphocytes, while terminally differentiated cells of the myeloid 
lineage include macrophages, dendritic cells, neutrophils, eosinophils, basophils, mast 
cells, erythrocytes (red blood cells) and megakaryocytes that generate platelets (18). 
More specifically, then, hematopoiesis is the acquirement of defining blood cell pheno-
types as a result of coordinated, cell-specific gene expression (19). Molecular pathways, 
including cytokine receptors and cell specific transcription factors, have been identified 
as regulators controlling the different blood cell lineages (19-21). Zhu and Emerson have 
proposed that it is the effects of both intrinsic transcription factors and external signaling 
pathways initiated by cytokines that govern stem cell fate decisions (21). 
Multicolour flow cytometry has permitted the identification of phenotypically 
distinct stem-cell and intermediate-precursor populations (6). The Weissman laboratory 
has proposed an ordered sequence of hematopoiesis, beginning with a subpopulation of 
long-term HSCs (defined phenotypically as LIN-IL-7Rα-SCA1+KIT+FLT3-Thy1lowCD34-) 
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(6). The LIN marker represents a group of antigens on mature hematopoietic cells; the 
LIN panel includes CD11b, Gr-1, B220, TER119, CD4, CD8, CD5, and CD3. These 
cells have the ability for life-long self-renewal and multilineage differentiation (6). 
Long-term HSCs give rise to short-term HSCs (defined phenotypically as LIN-IL-7Rα-
SCA1+KIT+FLT3lowThy1lowCD34+), which retain the ability for multilineage differen-
tiation potential, but have less self-renewal potential (6). The short-term HSCs give 
rise to the multipotential progenitors (MPPs) (defined phenotypically as LIN-IL-7Rα-
SCA1+KIT+FLT3lowThy1-CD34+), which have lost self-renewal potential but are still 
able to differentiate into all blood-cell types (6). From this point, the MPPs give rise 
to either the common lymphoid progenitor (CLP) (defined phenotypically as LIN-IL-
7Rα+SCA1lowKITlow) or the common myeloid progenitor (CMP) (defined phenotypically 
as LIN-SCA1-KIT+CD34+FcγRII-FcγRIII-) (23, 24). The Weissman model proposes that 
all myeloid cells arise from CMPs. The CMP goes on to give rise to more specified pro-
genitors including granulocyte/monocyte progenitors (GMPs) (defined phenotypically as 
LIN-SCA1-KIT+CD34+FcγRII+FcγRIII+), megakaryocyte/erythroid progenitors (MEPs) 
(defined phenotypically as LIN-SCA1-KIT+CD34-FcγRII-FcγRIII-), and as has recently 
been shown, basophil progenitors (25), as well as a shared macrophage and dendritic cell 
progenitor (MDP) (26). From these various progenitors, the terminally differentiated cell 
types are established. The hematopoietic lineage diversification system proposed by the 
Weissman group is summarized in Figure 1.1A. 
The Weissman model has recently been challenged by Jacobsen and colleagues, 
who propose that the erythroid lineage diverts much earlier, without going through a 
shared CMP stage (27). The Jacobsen model states that following differentiation from 
a long-term HSC into a short-term HSC the short-term HSC differentiates into either a 
MEP, or a lymphoid-primed multipotent progenitor (LMPP). The LMPP then differen-
tiates into the GMP, leading to granulocytes and macrophages, or the CLP, leading to 
NK cells, B cells and T cells (27). The Jacobsen model is illustrated in Figure 1.1B. The 
6
Figure 1.1 Current Models of Hematopoiesis.
Figure 1.1 adapted from Rosenbauer & Tenen 2007 (6) and Reya et al. 2001 (22)
(A) Classical/Weissman model of hematopoiesis. CLPs are thought to generate T and 
B-cells, while CMPs give rise to GMPs, MEPs, MDPs, and mast-cell and basophil pro-
genitors. (B) Jacobsen model of hematopoiesis. The Jacobsen model states that MEPs 
are the direct progeny of ST-HSCs, while all myeloid and lymphoid lineages are the 
progeny of LMPPs. 
Long-term (LT) and short-term (ST) hematopoietic stem cell (HSC); Multipotent progeni-
tor (MPP); Common lymphoid progenitor (CLP); Common myeloid progenitor (CMP); 
Granulocyte/macrophage progenitor (GMP); Megakaryocyte/erythroid progenitor (MEP); 
Macrophage/dendritic cell progenitor (MDP); Lymphoid-primed multipotent progenitor 
(LMPP).
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B
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Jacobsen model is most compatible with the finding that PU.1 deficient mice are devoid 
of CLPs and CMPs, but have relatively normal numbers of erythroid cells (6). Further-
more, several other alternative models of hematopoiesis have been proposed including 
but not limited to the stochastic model, the sequential restriction model, myeloid-based 
models, as well as models based on studies of transcription factors (28). In conclusion, 
while much progress has been made in understanding hematopoiesis, more research is 
still required to establish a complete pathway to the development of blood cells. 
1.3 Transcriptional regulation of myeloid cell development
Myelopoiesis is the developmental process of producing differentiated cells of 
the myeloid lineage from HSCs. Transcription factors play a pivotal role in myeloid cell 
differentiation (29-35).  The myeloid lineage comprises most of the cells of the innate im-
mune system and includes monocytes/macrophages, neutrophils, eosinophils, basophils, 
mast cells and dendritic cells (18). Erythrocytes (red blood cells) and megakaryocytes 
have also been traditionally considered part of the myeloid lineage, though that view has 
recently been challenged with the Jacobsen model (27). Myeloid cells, specifically granu-
locytes (collective term for neutrophils, eosinophils, and basophils) (18) and monocytes, 
are key mediators of the inflammatory response (32). Myeloid cells mediate recognition, 
ingestion, and destruction of foreign organisms, antigen presentation, cytokine produc-
tion, and other functions of the immune and inflammatory reactions (32). HSCs in fetal 
liver or in adult bone marrow give rise to GMPs, which in turn give rise to granulocyte, 
monocyte, and granulocyte/monocyte-colony forming units (CFU-G, CFU-M, CFU-GM) 
(33). Of note, GMPs share with CLPs the ability to generate myeloid dendritic cells (33).
Cell development and differentiation is defined by gene expression patterns 
(33). Accordingly, transcription factors play a pivotal role by inducing the expression 
of lineage-specific markers (33). While there is no single regulator of myelopoiesis, the 
formation of cells of the myeloid lineage is controlled by a relatively small number of 
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transcription factors that regulate expression of myeloid specific genes, such as those 
encoding receptors for macrophage colony-stimulating factor (M-CSF) and granulocyte 
macrophage colony-stimulating factor (GM-CSF)(6, 16, 30-32). Table 1.2 illustrates tran-
scriptional regulators of granulocytic and monocytic genes. Notably, numerous reports 
have identified two key, non-redundant, transcription factors as absolutely critical for 
normal myeloid cell development: PU.1 and C/EBPα (30-32). Knock-out studies of these 
factors reveal major distortion of myeloid development (36-41). Furthermore, aberrant 
expression of these two transcription factors has been shown to contribute to the patho-
genesis of AML (6, 32, 42-47).  As mentioned, in addition to transcriptional regulation, 
cytokine activity has also been shown to influence hematopoiesis (32). While signaling 
through cytokine receptors modulates factor activity, whether or not they can actually 
determine cell fate has been contested (32, 33). 
Although myelopoiesis cannot occur in the absence of either C/EBPα or PU.1, 
normal myeloid cell development also requires the cooperation of several other transcrip-
tion factors. The very first transcription factors to play a role, are those that orchestrate 
the formation of HSCs from earlier stem cells of the mesoderm: RUNX1 (AML1) and 
stem-cell leukemia factor, SCL (also known as T-cell acute lymphocytic leukemia pro-
tein, TAL1, encoded by the gene TAL1) (6). Confirmation of the importance of these two 
transcription factors, come from studies that illustrate that both RUNX1-/- and TAL1-/- mice 
are embryonic lethal and have no detectable hematopoiesis, (48, 49).  
C/EBPα is necessary for production of GMPs from CMPs (6). Interestingly, C/
EBPα is expressed by HSCs, myeloid progenitors (CMPs, GMPs), and granulocytes, but 
not by macrophages (24, 50). Several CEBPA gene knockout studies have demonstrated 
that lack of C/EBPα results in a block of the CMP to GMP transition (31). CEBPA-/- mice 
lack GMPs and granulocytes (neutrophils and eosinophils) but retain monocytes (36, 37).  
It is also necessary to highlight the early differentiation block of granulocytes in CEBPA-/-  
mice; C/EBPα is no longer required for granulocytic differentiation beyond the GMP 
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Table 1.2 Regulation of Granulocytic and Monocytic Genes. 
Table 1.2 adapted from Friedman 2002 (26) 
 
Protein Transcriptional Regulators of gene 
encoding protein 
Early-stage granulocytes 
mim-1 
Myeloperoxidase (MPO) 
Neutrophil elastase (NE) 
Myeloblastin (MBN) 
G-CSF receptor 
GM-CSF receptor 
CD13 
Lysozyme 
c-fes 
 
C/EBPs, c-Myb 
C/EBPs, PU.1, CBF, c-Myb 
C/EBPs, PU.1, CBF, c-Myb, Sp1 
C/EBPs, PU.1, c-Myb 
C/EBPs, PU.1 
C/EBPs, PU.1 
c-Myb, Ets-1 or Ets-2, c-Maf 
C/EBPs, PU.1 
PU.1, Sp1 
Early-stage monocytes 
M-CSF receptor 
Lysozyme 
 
C/EBPs, PU.1, CBF, c-Jun 
C/EBPs, PU.1 
 
Late-stage granulocytes 
gp91phox 
Lactoferrin (LF) 
FcγRI 
 
PU.1, IRF‐8, CDP 
C/EBPs, Sp1, CDP 
PU.1 
Late-stage monocytes 
Macrosialin 
Scavenger receptor (type I) 
Scavenger receptor (type II) 
CD14 
gp91phox 
CD11b 
CD18 
FcγRI 
FcγRIIIA 
 
PU.1, c‐Jun 
PU.1, c‐Jun 
PU.1, c‐Jun 
C/EBPs, Sp1 
PU.1, IRF‐8, CDP, Hox10A 
PU.1, Sp1 
PU.1, Sp1 
PU.1 
PU.1 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stage, as conditional deletion of CEBPA in GMPs allows for normal granulopoiesis (37). 
In addition to its role in myeloid differentiation, and regulation of myeloid specific genes 
(see Table 1.2), C/EBPα also controls stem-cell self-renewal properties (37) and coordi-
nates cell-cycle exit (51). 
The transcription factor c-Myb has also been implicated as a requirement for early 
granulopoiesis (33). Like MYC, MYB is a proto-oncogene that promotes proliferation and 
thus must be down-regulated for terminal myeloid differentiation to occur (34). Consis-
tent with c-Myb’s role in the early stages of differentiation is the fact that c-Myb activates 
early granulocyte genes including the genes encoding CD13, neutrophil elastase, myelo-
peroxidase, and myeloblastin (34) (Table 1.2). C-Myb is expressed in immature myeloid, 
lymphoid, and erythroid cells, and MYB-/- mice lack each of these lineages (30, 33). 
RARα is also connected with early granulocytic differentiation. While RARs are 
widely expressed, RARα is preferentially found in myeloid cells (52). Dominant inhibi-
tion of RARα arrests granulocytic differentiation at the promyelocytic stage (10). Im-
portantly, RARα activates the CCAAT/enhancer binding protein epsilon (C/EBPε) gene 
promoter linking RARα to granulocyte development (53).
From the GMP stage, the next major milestone is designation of granulocytic 
versus monocytic/macrophage fate. PU.1 binding partners have been shown to play a role 
in terminal monopoiesis. PU.1 interaction with the interferon-γ (IFN- γ)-responsive tran-
scription factor IRF8 (interferon regulatory factor 8) (also known as interferon consensus 
sequence binding protein, ICSBP) has been implicated in monopoiesis (31). In the my-
eloid lineage, IRF8 is expressed by progenitors and macrophages, but not by granulocytes 
(54). IRF8-/- mice have reduced macrophages and increased granulocytes (55). 
Other transcription factors, including c-Jun and c-Fos, also cooperate with PU.1 
to regulate myeloid genes and monocytic differentiation (56-58). C-Jun assists PU.1 by 
either binding to adjacent DNA elements or by direct physical interactions. Physical in-
teraction occurs between PU.1 and c-Jun via their DNA binding domains; this interaction 
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permits the pair to activate gene transcription (59).  Jun proteins (c-Jun, JunB, JunD) are 
part of the bZIP, AP-1 subfamily of transcription factors that heterodimerize with c-Fos, 
Fos B, Fra1 or Fra2 (31). Intriguingly, c-Jun and c-Fos can also heterodimerize with C/EBPα to induce monocyte commitment (60). 
Furthermore, the Maf transcription factor family (MafB, c-Maf) can zipper with 
Fos or Jun family members (30).  MafB is expressed in monocyte/macrophage cells and 
exogenous MafB or c-Maf leads to monocytic differentiation (31). A role for MafB in late 
but not early monocyte lineage development has been suggested (31). 
In regards to late granulocytic specification, transcription factors involved include C/EBPε, and growth-factor independence-1 (GFI1). While C/EBPα is the predomi-
nant isoform in immature granulocytes, C/EBPε predominates mature granulocytes (32). 
A clear role for C/EBPε in the regulation of terminal granulopoiesis is evident from the 
phenotype of C/EBPε deficient mice, which have immature granulocytes (neutrophils and 
eosinophils) that fail to develop normally past the promyelocyte stage and lack secondary 
granules (61-63). As well, the presence of C/EBPε regulatory sites in the promoters of 
genes expressed in neutrophils is highly suggestive of C/EBPε as a key player in granu-
locytic differentiation (30). Similarly, GFI1-/- mice lack neutrophilic granulocytes (6). 
Notably, the development of early myeloid progenitors, including GMPs, was normal in 
GFI1-/-  mice, but neutrophilic differentiation was blocked beyond the promyelocyte stage 
(64). This finding confirms the role of C/EBPα in early granulocyte development, and 
illustrates the significance of other factors, such as GFI1, in later stages of granulopoiesis. 
Finally, GFI1-/-  mice accumulated neutrophil precursors that expressed monocyte-spe-
cific genes in addition to early granulocyte markers. The abnormal neutrophil population 
present in GFI1-/- mice correlates with the fact that GFI1 contains a transcriptional repres-
sor and may function to repress monocyte/macrophage lineage traits during granulocytic 
maturation (64). 
The transcription factor Specificity Protein 1 (Sp1), has also been implicated in 
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terminal granulopoiesis (as well as monopoiesis). This implication is based on the fact 
that Sp1 regulates several granulocytic and monocytic genes, including the genes encod-
ing lactoferrin (LF) (granulocytic), CD14 and CD11b (monocytic) (see Table 1.2) (30). 
Furthermore, Sp1 is expressed at particularly high levels in maturing granulocytes (30).
Like GFI1, recent studies have shown that the transcription factors early growth 
response proteins 1 and 2 (EGR1, EGR2), NGF1-A-binding protein 2 (NAB2), CCAAT 
displacement protein (CDP), and Homeobox protein Hox-A10 (HoxA10) repress terminal 
differentiation (31).  Laslo et al. have identified the EGR proteins and NAB2 as possible 
repressors of granulopoiesis, while stimulating monopoiesis (65). Evidence for the no-
tion that EGR:NAB2 complexes repress granulopoiesis stems from the fact that EGR2 or 
NAB2 knockdown induces neutrophilic genes, including GFI1, and EGR2:NAB2 repress-
es the GFI1 promoter (65). GFI1 represses the EGR2 promoter (65), providing further 
support for GFI1 as a transcriptional repressor of monopoiesis. In maturing neutrophils, 
the gp91phox promoter region, (gp91phox is a late stage granulocyte and monocyte gene) 
is repressed by both CDP and HoxA10 (66-67). CDP represses transcription by compet-
ing with transactivators for the same site (DNA elements that resemble the 5’-CCAAT-3’ 
motif) (68). Work by Skalnik et al., as well as Eklund et al., suggest that levels of CDP 
and HoxA10 decrease during terminal neutrophil and monocyte differentiation (66-67). 
Due to the fact that HoxA10 is preferentially expressed in immature myeloid cells (33), it 
has been postulated that HoxA10 plays a role in maintaining an earlier stage in myelopoi-
esis and inhibiting terminal differentiation (33). In conclusion, myeloid cell development 
is achieved via cooperative gene regulation, protein-protein interaction, autoregulation, 
regulation of factor levels, and induction of cell cycle arrest (33).
1.4 Purine-Rich Box Binding-1 (PU.1) 
PU.1 is a member of the family of E26 transformation specific (ETS) transcription 
factors. Members of this family of proteins all contain a characteristic winged-helix-turn-
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helix DNA binding domain that binds DNA sequences with a GGA core (“GGAA”) (69-
70). PU.1 binds as a monomer to the purine-rich consensus DNA sequence (from which it 
derived its name) 5’GAGGAA-3’ (PU box) via its C-terminal ETS DNA binding domain 
(71). 
In 1988, PU.1 was first discovered as a putative oncogene isolated from a murine 
Friend virus-induced erythroleukemia (72). The murine erythroleukemia was induced by 
a proviral insertion of the retroviral spleen focus forming virus (SFFV) (72). The gene 
encoding PU.1 became known as SPI1 (SFFV proviral integration site-1), in humans, and 
Sfpi1, in mice (72). Interestingly, Paul et al. found that overexpression of PU.1 blocks 
erythroid differentiation (73).  The murine PU.1 protein contains 266 or 272 amino acids 
due to two potential translation start codons, and is ~42 kilodaltons (kDa) in size (74). 
The human PU.1 protein is quite similar, demonstrating 85% homology with murine 
PU.1 (75). As indicated, PU.1 expression is restricted to blood cells (71), where it plays a 
fundamental role in the development of both myeloid and lymphoid lineages (41).  
In addition to DNA binding, the C-terminal ETS DNA binding domain of PU.1 
can also interact with other proteins, including C/EBPα, CCAAT/enhancer binding pro-
tein beta (C/EBPβ), c-Jun and GATA-binding factor 1 (GATA-1) (59, 76-78) (Figure 1.2). 
PU.1 contains two other functional domains: an N-terminal transactivation domain, incor-
porating an acidic and a glutamine rich region, and a PEST domain (79). While PU.1 acti-
vates transcription via its N-terminal domain (79), this region also allows for interaction 
with other proteins such as GATA-1, TATA box binding protein (TBP) and Retinoblasto-
ma protein (pRb) (78, 74) (Figure 1.2).  TBP is a subunit of the basal transcriptional com-
plex TFIID, which increases RNA polymerase II activity, and pRb is a regulator of cell 
cycle progression (74). The PEST domain is located between the transactivation domain 
and the ETS domain; PEST was named after its high content of proline (P), glutamic acid 
(E), serine (S), and threonine (T). This domain is involved in protein stability/degrada-
tion (74, 80). Furthermore, phosphorylation of PU.1 within its PEST domain, allows it to 
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Figure 1.2 Protein-protein interactions involving PU.1. The transcription factor PU.1 
is illustrated, with its three domains: N-terminal transactivation domain (blue), PEST do-
main (red), and C-terminal ETS DNA binding domain (green). The proteins that interact 
with each domain within PU.1 are also labeled within the corresponding domain.
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interact with IRF4 and IRF8 (31) (Figure 1.2). 
1.5 The expression and regulation of PU.1 in myeloid development
PU.1 is widely expressed among the various blood lineages. PU.1 is expressed in 
HSCs, CMPs, CLPs, GMPs, monocytes, granulocytes, and B cells (6). Recent analysis 
has shown that the absence of PU.1 impairs the ability of HSCs to self-renew and pre-
vents differentiation into CMPs and CLPs (38, 81). Importantly, PU.1 expression levels 
appear to be a crucial determinant in cell-fate decisions of both myeloid and lymphoid 
progenitors. PU.1 is expressed at similar levels in HSCs, CMPs, CLPs, and B cells, but 
its expression increases substantially during terminal myeloid (granulocytic and mono-
cytic) differentiation (47, 82-83). Furthermore, Singh’s group illustrated how high levels 
of PU.1 induce commitment to the myeloid lineage, while lower levels induce B cell de-
velopment (84). By contrast, PU.1 expression is downregulated early on during erythroid 
and T cell differentiation (72, 85-86).  Recent evidence, however, has shown that certain 
subsets of T cells must re-express PU.1 during terminal differentiation. This includes a 
subset of IL-9 producing helper T cells (87). In cell lines, PU.1 is expressed by myeloid 
and B cells, but not by T cell lines (71, 88). When examining the myeloid lineage, specifi-
cally, it has been observed that high PU.1 levels support the production of macrophages, 
whereas low PU.1 levels support granulocyte production (47, 89-90).  For example, one 
study found that expression of low levels of PU.1 in Sfpi1-/- cells induces granulopoiesis, 
while high levels induce monopoiesis (89). As well, expression of PU.1 at 20% of wild-
type levels resulted in a loss of monopoiesis, but maintenance of granulopoiesis (47). In 
short, it is clear PU.1 expression is absolutely critical throughout myeloid cell develop-
ment, beginning from the HSC stage (6). 
Due to the significance of PU.1 levels in hematopoietic lineage commitment, 
regulation of PU.1 expression is essential. Many groups have shown that inappropriate 
expression of PU.1 will lead to anomalous development of the hematopoietic system and 
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may result in leukemia (91). Several different transcription factors regulate PU.1 expres-
sion, including Octamer (Oct-1 and 2), Sp1, GATA-1, C/EBPα, RUNX1, and PU.1 itself. 
Chen et al. have reported an octamer binding site 55 bp upstream of the transcriptional 
start site (TSS) (92). While both Oct-1 and 2 can bind specifically to the site -55 bp of the 
Sfpi1 promoter, Oct-2 expression is limited to B cells, while Oct-1 is expressed ubiqui-
tously (92). Interestingly, a recently identified octamer coactivator, known as Bob1 (93), 
OBF-1 (94), or OCA-B (95), is expressed exclusively in B cells (92). This may explain 
why the octamer site is relatively more important for PU.1 expression in B cells than 
myeloid cells, where PU.1 itself is most important (92). The same group detected both a 
Sp1 and PU.1 binding site within the Sfpi1 promoter at -40 bp and +20 bp, respectively 
(92, 96).  In myeloid cells, the PU.1 binding site (+20 bp) is located in the 5’-untranslated 
region of the Sfpi1 promoter and has been shown to be functionally important, leading to 
an autoregulatory loop (96). In addition, Okuno et al. recently proposed a second poten-
tial autoregulatory mechanism involving an upstream regulatory element (URE). Okuno 
et al. demonstrate that PU.1 binds a distal site located 14 kb upstream of the TSS (in 
mice) and mutation of this site, abolishing PU.1 binding, results in a decrease in PU.1 ex-
pression (97). Intriguingly, deletion of the URE in mice reduces PU.1 expression to 20% 
of wild-type levels in HSCs, myeloid cells, and B cells (47). The same distal element is 
located 17 kb upstream of the TSS in humans (6). Thus, PU.1 may be able to positively 
regulate its own expression through both the URE and the PU.1 promoter. RUNX1 also 
binds to the same distal enhancer as PU.1 itself, thereby controlling PU.1 expression (98). 
RUNX1 binds to three sites within the URE of PU.1 and regulates PU.1 both positively 
and negatively in a lineage dependent manner (98). The mutual antagonism between 
PU.1 and GATA-1 is another well-known example of PU.1 gene regulation. A GATA-
1 binding site 15 bp upstream of the TSS has been observed (52, 92, 96). Furthermore, 
Zhang et al. demonstrate that interaction between PU.1’s ETS domain and the C-terminal 
zinc finger of GATA-1 inhibits PU.1 activation of myeloid target genes (99). They also 
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show that GATA proteins inhibit binding of PU.1 to c-Jun, a coactivator of PU.1 transac-
tivation (99). The ability of GATA-1 to repress myeloid gene expression via interaction 
with the PU.1 ETS DNA binding domain and subsequent interference of PU.1 function 
has been confirmed by Nerlov et al. (100). Similarly, C/EBPα blocks the function of PU.1 
through protein-protein interaction (73). As well, the leucine zipper in the DNA binding 
domain of C/EBPα interacts with the β3/ β4 region in the ETS domain of PU.1, resulting 
in displacement of c-Jun. (78). Finally, PU.1 expression is also upregulated by the Notch1 
signaling pathway (101).
1.6 The role of PU. 1 during myeloid development 
Knock-out, knock-in, overexpression, reduction, and restoration studies clearly 
indicate the problems that arise in the absence of normal PU.1 levels. Two labs, in partic-
ular have played pivotal roles in our understanding of PU.1 by creating an Sfpi1-/- mouse 
model. The first lab, of Dr. Harinder Singh, replaced PU.1’s ETS DNA binding domain 
with the neomycin resistance gene. In their model, Sfpi1 deletion was embryonically 
lethal between days 16.5 and 18.5 of gestation. Upon analysis of PU.1 (-/-) fetal liver, no 
myelocytes (or lymphocytes) were detected (40), indicating an early and severe differen-
tiation block on myelopoiesis. The second group, Dr. Richard Maki’s, created their Sfpi1-/- 
mouse by inserting the neomycin-resistance gene into the ETS domain. Dr. Maki’s group 
was able to generate pups, though they died of septicemia within 2 days, and again no 
mature granulocytes or macrophages were detected (41).  Interestingly, Sfpi1-/- pups were 
able to survive up to 2 weeks with antibiotics and these older mice contained a small pop-
ulation of abnormal neutrophils and macrophages (41). Thus, both models demonstrate 
obvious defects in myeloid cell development. While a complete absence of PU.1 expres-
sion has severe effects, other groups have looked at a reduction in PU.1 expression and 
found similar problems.  Dr. Daniel Tenen’s group was the first to report that AML could 
be induced by a decrease in PU.1 expression (47).  Tenen’s group generated a hypo-
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morphic Sfpi1 allele, by replacing the -14 kb URE with a neomycin resistance gene. Mice 
homozygous for this ΔUREneo allele expressed PU.1 at 20% of normal levels (47). These 
mice had an accumulation of abnormal, immature myeloid precursors in the bone marrow 
and spleens, that were responsive to G-CSF, but not M- or GM-CSF (47). Furthermore, 
myeloid differentiation was blocked in mice homozygous for the Sfpi1 allele that reduces 
PU.1 expression, and these mice eventually developed AML (43).
Our laboratory has generated a novel hypomorphic allele of Sfpi1 termed BN, which 
also produces PU.1 at 20% of wild-type levels (102). The allele was generated by muta-
tion of the first coding exon (102). Within this region, two ATG translation start sites were 
replaced with a β-lactamase gene/neomycin resistance cassette (102).  A third translational 
start codon exists within Sfpi1 enabling Sfpi1BN alleles to be transcribed, but resulting in a 
slightly truncated protein. Due to altered transcriptional regulation, it also results in PU.1 
being expressed at a reduced level. Nonetheless, the protein itself is fully functional (102). 
Neonatal mice homozygous for the mutated Sfpi1 allele (Sfpi1BN/BN mice) are character-
ized by a hyperproliferation of immature myeloid cells in their bone marrow and spleen, 
as well as a complete absence of B-cells (98). Sfpi1BN/BN mice survive only 1-3 weeks fol-
lowing birth and demonstrate severe phenotype abnormalities, including osteopetrosis and 
reduced physical size (102).
1.7 Transcriptional targets of PU.1
The importance of PU.1 in myeloid cell development is highlighted by the pres-
ence of PU.1 binding motifs in the regulatory sequences of almost all myeloid-specific 
genes, as illustrated in Table 1.2 (6, 32). Notable PU.1 target genes include the genes en-
coding the receptors for essential cytokines as M-CSF, GM-CSF, and granulocyte colony-
stimulating factor (G-CSF) (103-106). The growth factors that the M-CSFR, GM-CSFR, 
and G-CSFR bind are required for the proliferation and differentiation of myeloid cells. 
PU.1 also activates genes necessary for the myeloid phenotype, including the genes en-
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coding CD11b, CD18, FcγRI/IIIA, and scavenger receptors, type I and II (107-111) (see 
Table 1.2). CD11b is a cell surface marker expressed on mature monocytes, macrophages, 
and granulocytes (107); the β2 leukocyte integrin CD18, together with CD11b forms 
the complex macrophage-1 antigen, Mac-1 (complement receptor 3, CR3), which plays 
several important roles in immune and inflammatory responses (108). The high-affinity 
Fc gamma receptor I (FcγRI) and the low-affinity Fc gamma receptor IIIA (FcγRIIIA) 
are both expressed exclusively in the myeloid lineage and are receptors for the Fc domain 
of immunoglobulin G (IgG). They play an important role in innate immunity through 
their ability to induce phagocytosis and trigger antibody-dependent cellular cytotoxicity 
(109-110). Expression of type I and II scavenger receptors (SRs) is highly restricted to 
monocytes/macrophages; SRs are maximally expressed during monocyte to macrophage 
differentiation (111). Finally, recent studies by Ghisletti et al. demonstrate that PU.1 helps 
control expression of inflammatory genes, such as the genes encoding interleukin-1 beta 
(IL-1 β), interleukin-18 (IL-18), interleukin-12 subunit p40 (IL12p40 subunit), and tumor 
necrosis factor (TNF), in macrophages (112).
1.8 The Cell Cycle
Cell cycle exit is necessary for terminal differentiation to occur (33). Without cell 
cycle arrest, immature cells will continue to proliferate, possibly leading to the develop-
ment of cancer. One of the hallmarks of cancer is cell cycle deregulation (113-114). Cell 
cycle deregulation can occur at different levels of the cell cycle control network (115).
The cell cycle is a process by which DNA is replicated and then separated into 
two new cells (115). The process is divided into four distinct stages: G1, S, G2 (collec-
tively known as interphase) (116), and mitosis (M) (115). DNA replication occurs during 
S phase and is preceded by G1 phase, in which the cells are preparing for DNA synthesis. 
Following synthesis, the cells enter a second gap phase (G2), in which the cell prepares 
for mitosis. The actual segregation of chromosomes into two separate cells occurs during 
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Figure 1.3 Control of the cell cycle. The stages of the cell cycle and sites of activity 
of regulatory CDK/cyclin complexes are presented. Cyclin dependent kinase inhibitors 
(CKIs), p15 and p27 are also indicated. As well, the G1 to S phase transition involving 
pRb and E2F1 is illustrated.
P (phosphorylation); * demonstrates the CDK7-cyclin H complex throughout all phases 
of the cell cycle; → (activation);   (repression)
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mitosis, which is divided into prophase, metaphase, anaphase, telophase (115). A resting 
state, known as G0, also exists within the cell cycle. G0 is a departure from the G1 stage 
and cells can enter G0 before making the commitment to S phase. Cells in the G0 stage 
are non-growing and non-proliferating (115) (Figure 1.3).
Transition through the various phases of the cell cycle is highly regulated; it is 
controlled by numerous mechanisms including cyclin-dependent kinases (CDKs), cy-
clins, CDK inhibitors (CKIs), phosphorylating events, and CDK activating enzymes. 
CDKs are key regulators of the cell cycle. They are a family of serine/threonine protein 
kinases that are activated at specific points of the cell cycle (115).  Once activated CDKs 
phosphorylate other proteins to induce downstream processes necessary for cell cycle 
progression (116-117). Five of the nine CDK family members are active during the cell 
cycle at various points. Figure 1.3 illustrates the five CDK family members (CDK4, 
CDK6, CDK2, CDK1, CDK7) that are active during the cell cycle and the particular 
stage at which their presence is required. CDK7 acts in combination with cyclin H as 
CDK activating kinases (CAK) (118); the CAK complex is required throughout all cell 
cycle phases (115). Furthermore, CDKs require activation from another group of regula-
tory proteins, known as cyclins, that complex with CDKs in order to regulate the cell 
cycle. While CDK protein levels remain stable during the cell cycle, cyclin levels fluctu-
ate; when the level of a cyclin protein rises it is able to activate its particular CDK (115). 
As illustrated, different cyclins act at different stages of the cell cycle to activate different 
CDKs. D cyclins (D1, 2, and 3) bind to CDK4 and CDK6 to permit entry into G1 phase. 
Cyclin E associates with CDK2 to regulate progression from G1 to S phase. A CDK2-
cyclin A is required during S phase. In late G2 and early M, a CDK1-cyclin A complex 
is formed to promote entry into M. The remainder of M is regulated by a CDK1-cyclin 
B complex (115) (Figure 1.3). In addition to cyclins, CDK activity is further regulated 
by phosphorylation. Some CDKs, such as CDK1, require phosphorylation to become 
fully active 115) (Figure 1.3). Phosphorylation induces conformational changes that en-
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able CDKs to better bind cyclins (119). While CDK activating kinases, such as the CAK 
complex act on CDKs, so do CDK inactivating kinases. Similarly, cell cycle inhibitory 
proteins, known as CDK inhibitors (CKI) also regulate CDK activity (115). There are two 
relevant families of CKIs: the INK4 family, which includes p15 (INK4b), p16 (INK4a), 
p18 (INK4c) and p19 (INK4d), and the Cip/Kip family, which includes p21 (Waf1, Cip1), 
p27 (Cip2), and p57 (Kip2) (115). The INK4 family inactivates G1 CDKs (CDK 4 and 6) 
by preventing cyclin binding (120) (Figure. 1.3).  The Cip/Kip family inactivate CDK-
cyclin complexes (121), specifically the G1 CDK-cyclin complexes, and to a lesser extent 
the CDK1-cyclin B complex (122) (Figure 1.3).
 As mentioned, once active, CDKs are able to phosphorylate target proteins, which 
ultimately leads to cell cycle progression. The pathway controlling the progression of 
cells from G1 into S phase is well established (123-124) and involves the CDK4/6-cyclin 
D complex and its substrate, the product of the retinoblastoma tumour suppressor gene, 
pRb (115).  In this scenario, CDK4/6 phosphorylates pRb in early G1 phase, resulting in 
disruption of the pRb-HDAC (histone deacetylase) complex and release of the transcrip-
tion factors E2F1 and DP1 (115) (Figure 1.3).  
E2F1 and DP1 are members of two different groups of proteins that heterodimer-
ize to induce transcription (123, 125). The two different groups are the E2F gene fam-
ily consisting of six E2F genes (E2F1-E2F6), and the DRTF (differentiation regulated 
transcription factor) protein (DP) gene family, which consists of two DP genes (DP1 and 
DP2) (123). Thus, heterodimers contain a subunit encoded by the E2F gene family and a 
subunit encoded by the DP gene family (123). E2F1-DP1 heterodimers positively regu-
late transcription of genes whose products are required for S phase progression, including 
cyclin A and cyclin E (115).
1.9 E2F1, PU.1 and AML
It is now well-established that the transcription factor E2F1 can promote entry 
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into S phase from G1 (126-127). As indicated above, E2F1 (when complexed with a 
DP) controls the transcription of genes essential for cell division; these include genes 
encoding cell cycle regulators (such as the cyclins indicated above), enzymes involved 
in nucleotide biosynthesis (such as thymidine kinase), and the main components of the 
DNA-replication machinery (126). The potency of E2F1 as a transcriptional activator 
has been shown through overexpression of the protein, which induces quiescent cells to 
re-enter the cell cycle (127-129). Furthermore, deregulation of E2F1 activity appears to 
be a characteristic of human cancers (125, 130). E2F1 is regulated via association with 
pRb; once pRb is phosphorylated by CDK-cyclin complexes, E2F1 is released. Thus, 
pRb restricts cell cycle progression by maintaining E2F1 and the disassociation of E2F1 
from pRb drives proliferation (123). The idea that defects in regulation and inappropri-
ate release of E2F1 might induce cancer, are illustrated by the fact that overexpression 
of E2F1 can induce transformation of primary cells (131-133). Moreover, Gibbs et al. 
have shown that deregulated expression of E2F1 blocks terminal myeloid differentiation, 
resulting in proliferation of immature myeloid cells (134). In addition to inducing prolif-
eration, deregulated E2F1 activity can also trigger apoptosis (122, 126). This functional 
paradox of E2F1 has been investigated and the results demonstrate that E2F1 can have 
both oncogenic (through its role in cell cycle progression) and tumor-suppressive effects 
(through apoptosis induction) (130). 
 Certain hematopoietic transcription factors, such as, c-Myb, and c-Myc, promote 
proliferation, and are down-regulated upon differentiation (34), while others, such as C/
EBPα promote cell-cycle arrest (6).  Several different mechanisms by which C/EBPα acts 
on the cell cycle have been reported. The most important mechanism, however, appears 
to be repression of E2F1 activity. This is suggested by the fact that targeted mutation in 
the gene encoding C/EBPα that results in defective repression of E2F1 failed to support 
granulocytic differentiation (6). On the other hand, mice lacking the CDK2/CDK4-
binding domain of C/EBPα (inhibition of cyclin-dependent kinase 2 activity is another 
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mechanism by which C/EBPα acts on the cell cycle) were normal (6). The importance of 
PU.1 in terminal myeloid differentiation suggests that a similar role for PU.1 as C/EBPα, 
in regulating the cell cycle, may exist. 
1.10 Hypothesis
The increased proliferation and impaired differentiation of immature myeloid cells in 
Sfpi1BN/BN mice implies that PU.1 is necessary for cell cycle exit during myeloid differentia-
tion. In this scenario, when PU.1 levels are decreased, the cell cycle is no longer regulated 
and myeloid progenitors continue to expand uncontrollably, resulting in AML. We have 
found that PU.1 transcript levels are inversely correlated with the cell cycle regulator, 
E2F1. E2F1 functions to promote G1 to S phase progression, and deregulation of E2F1 is 
associated with cancer. This suggests that PU.1 regulates cell cycle at least in part by re-
pression of E2f1 expression. Consistent with the idea that PU.1 represses E2F1 is the fact 
that PU.1 levels increase during myeloid terminal differentiation, when cell cycle exit must 
occur (6, 50, 87, 88).
In conclusion, I intend to investigate the precise mechanism of how PU.1 works to 
regulate proliferation and differentiation of hematopoietic stem cells (HSCs) and its role 
in the development of AML. In order to conduct these investigations, I have formed the 
following hypothesis:
We hypothesize that PU.1 represses E2F1 to regulate cell cycle exit in myeloid cells.
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CHAPTER 2: MATERIALS AND METHODS
2.1 Mouse Strains
Our laboratory has generated a novel hypomorphic allele of Sfpi1 termed BN, 
which produces PU.1 at 20% of wild-type levels (102). Sfpi1+/BN mice were maintained as 
an Sfpi1+/BN colony in the West Valley Barrier facility at Western University (London, On-
tario, Canada). Sfpi1+/BN mice were mated to breed Sfpi1BN/BN neonates. Animal husbandry 
and breeding were conducted in compliance with the University of Western Ontario 
Animal Care and Veterinary Services Standard Operating Procedures. Polymerase Chain 
Reaction (PCR) was used to genotype mice in colony using primers listed Table 2.1. 
2.2 Cell Culture
Complete media contained 10% fetal bovine serum (FBS) (Wisent, St-Bruno, 
QC), penicillin (100 U/ml)/streptomycin (100 μg/ml) (Mediatech, Manassas, VA), L-
glutamine (0.292 mg/ml) (Mediatech), 2-mercaptoethanol (5 x 10-5 M) (Sigma-Aldrich, 
St. Louis, MO), and HEPES (5 mM) (Sigma-Aldrich). GP + E-86 packaging cells and 
platinum-E (Plat-E) retroviral packaging cells were both grown in complete Dulbecco’s 
Modification of Eagle’s Medium (DMEM) medium (Mediatech). BN cells were grown in 
complete Iscove’s Modification of DMEM medium with L-glutamine and 25 mM Hepes 
(Mediatech). The cytokine GM-CSF (1 ng/ml) was added. 
2.3 Generation of Inducible System
The Retro-X Tet-On 3G Inducible Expression System was purchased from Clon-
tech (Mountain View, CA). In order to clone our gene of interest (PU.1) into the Clontech 
response vector (pRetroX-TRE3G vector), an additional EcoR1 site was first added to the 
PU.1 cDNA sequence part of the MIG-PU.1 vector using PCR (primer sequences listed 
in Table 2.1). Following amplification, the PCR product was cloned into the StrataClone 
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Table 2.1 PCR and RT-qPCR primer sequences. 
 
 
Primer Name 
 
Sequence 
PCR ­ genotyping 
Sfpi1 Primer 1 5’ CGGCCAGAGACTTCCTGTAG-3’ 
Sfpi1 Primer 2 5’-AAGTTGGCCGCAGTGTTATC-3’ 
Sfpi1 Primer 3 5’-GCTCTTCGTCCAGATCATCC-3’ 
Sfpi1 Primer 4 5’-ATGGTCACACATCCCAAAGC-3’ 
PCR – addition of EcoR1 site 
3XFLAG EcoR1 forward 5’-GGAATTCGCCGCCATGGACTACAAAGAC-3’ 
3XFLAG EcoR1 reverse 5’-GGAATTCGTTGGGCCCTCTAGATC-3’ 
PCR – addition of Bg1II and EcoR1 sites 
TET3Gfwd-ATG-Bg1II 5’-ACGTAGATCTATGTCTAGACTGGACAAGAGCAAAGTC-3’ 
TET3Grev-TAA-EcoRI 5’ACGTGAATTCTTACCCGGGGAGCATGTC3’ 
qPCR 
E2f1 cDNA forward 5’-TCCCTGGGGAGTTCATCAGC-3’ 
E2f1 cDNA reverse 5’-CTAATGCCCTCACCCTCCTCG-3’ 
 
PCR Cloning Vector (pSC-A-amp/kan) (Agilent Technologies, La Jolla, CA) in order to 
enhance the efficiency of restriction enzyme cutting and thus the generation of EcoR1 
5’ overhangs. The PCR product is able to be cut out of the pSC-A-amp/kan vector with 
100% efficiency due to the supercoiled nature of the vector and the PCR product’s loca-
tion within the vector. StrataClone SoloPack competent bacteria cells were used in the 
transformation to clone the PU.1 PCR product into the pSC-A-amp/kan vector. Following 
confirmation that the PU.1 PCR product had been successfully cloned into the pSC-A-
amp/kan vector, the entire product was retransformed in preparation for maxi-prep. The 
entire product was then maxi-prepped in order to amplify and produce high DNA yields. 
The pRetroX-TRE3G vector was then digested with EcoR1 in preparation for ligation of 
insert. Following maxi-prep and using EcoR1, PU.1 was excised from the pSC-A-amp/
kan vector and ligated into the pRetroX-TRE3G vector using T4 DNA ligase. Ligated 
vector and insert were transformed and bacteria colonies were assessed for successful 
cloning of insert into vector using sequencing (to ensure insert was in correct orientation). 
Once successful cloning had been established the pRetroX-TRE3G vector with PU.1 
cDNA insert was once again retransformed, maxi-prepped and sequenced.
The regulator vector consisted of the Tet-On 3G transactivator genomic fragment 
cloned into the MIGR1 vector. Bg1II and EcoR1 restriction sites were PCR amplified 
(using primers listed in Table 2.1) into the Tet-On 3G gene, part of the pRetroX-Tet3G 
vector. The Tet-On 3G gene was then PCR amplified out of the pRetroX-Tet3G vector 
using TET3Gfwd-ATG-Bg1II and TET3Grev-TAA-EcoRI primers (listed in Table 2.1). 
The MIGR1 plasmid was digested with  EcoR1 and Bg1II and the Tet-On 3G gene was 
inserted into the MIGR1 plasmid by sticky end ligation. Separate response and regulator 
retroviral supernatants were produced (see below).
2.4 Retrovirus Production
Platinum-E (Plat-E) retroviral packaging cells were used to generate retroviral su-
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pernatants using polyethylenimine (PEI) transfection. Twenty-four hours before transfec-
tion, Plat-E cells were plated at a concentration of 5 x 106 cells in a 10 cm Petri dish and 
incubated at 37°C overnight. The next day, media (DMEM complete) was removed and 
replaced with 10 ml of fresh, serum-free media. Cells were incubated in the serum-free 
media for two hours at 37°C prior to transfection. For transfection, 1 ml of serum-free 
DMEM complete with 150 mM of NaCl, 1 μg of pCL-Eco plasmid, and 9 μg of DNA of 
interest were mixed and vortexed for 15 seconds. Following vortex, 25 μl of PEI (1 μg / 
μl) (Polysciences, Warrington, PA) was added to the mixture, the mixture was vortexed 
and the entire solution was incubated at room temperature for 20 minutes without distur-
bance. Finally, 1 ml of the DNA/PEI solution was added to Plat-E cells, followed by 1 ml 
of DMEM complete media to ensure cells were not serum starved overnight. Transfected 
cells were incubated overnight at 37°C. All media was removed the next morning and 
replaced with 2 ml of DMEM complete. Retrovirus-containing supernatant was harvested 
48 hours post transfection.
2.5 Retroviral Transduction of BN cells
BN cells were infected by resuspension in cell-free retroviral supernatants and 
centrifugation at 3100 rpm for 3 hours in the presence of polybrene (10 μg /ml). Follow-
ing centrifugation retroviral supernatant was removed and 1 ml of fresh media was added. 
Cells were incubated for 48 hours post infection to allow retroviral integration and pro-
tein expression.
2.6 Cell Cycle Analysis
The BD Pharmingen BrdU Flow Kit was purchased from BD Biosciences (Mississauga, 
ON, Canada). Bromodeoxyuridine (BrdU) incorporation was measured by flow cytom-
etry with an allophycocyanin (APC ) BrdU Flow Kit according to the manufacturer’s 
protocol. Briefly, cells were labeled with BrdU for 6 hours at 37°C.  Cells were incubated 
32
with the APC-conjugated anti-BrdU antibody using a 1:800 fold dilution. Staining with 
7-amino-actinomycin D (7-AAD) was also conducted to determine cell cycle position. 
For 7-AAD staining, cells were suspended in PBS containing 0.5 M EDTA (pH 8.0) and 
0.5 % BSA and then incubated with 7-AAD (BD Pharmingen).
2.7 Real-time PCR
RNA was extracted with TRIzol Reagent (Life Technologies, Carlsbad, CA) 
and reverse-transcribed using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA). 
Quantitative PCR (qPCR) was then performed using the iQ SYBR Green Supermix Kit 
(Bio-Rad) and Rotor-Gene 6000 (Corbett Life Sciences, Valencia, CA). Relative mRNA 
transcript levels were normalized to beta-2-microglobulin (B2M) as a reference gene and 
compared between samples using the comparative threshold (Ct) cycle method (135). 
Results are presented as the mean and SD of three experiments performed in triplicate. 
Primer sequences for E2f1 forward and reverse primers are listed in Table 2.1.
2.8 Immunoblotting
Cells were lysed with 6X Laemmli lysis buffer. Proteins from whole cell lysates 
were resolved by SDS-PAGE and transferred to a nitrocellulose membrane (Thermo 
Scientific, Waltham, MA) using a Trans-Blot SD Semi-Dry Electrophoretic Transfer 
Cell (Bio-Rad). Immunoblotting was performed with polyclonal rabbit anti-PU.1 anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA), polyclonal rabbit anti-E2F1 antibody 
(Thermo Scientific), polyclonal goat anti-actin antibody (Santa Cruz Biotechnology), 
HRP-conjugated anti-rabbit secondary antibody (Pierce, Rockford, IL, USA) and HRP-
conjugated anti-goat secondary antibody (Pierce). All antibodies were diluted according 
to the manufacturer’s protocol. Immunoreactive proteins were visualized with SuperSig-
nal West Pico Chemiluminescent Substrate (Thermo Scientific).
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2.9 Transplantation Studies 
Non-obese diabetic/severe combined immunodeficient/IL-2 receptor gamma chain 
null (NOD/SCID/γc-/-) (NSG) mice received 300 rad of irradiation prior to injection. NSG 
mice were used as they are the most immunodeficient xenotransplantation model to date 
(136). NSG mice not only lack T and B cells (like the NOD/SCID mouse), but also have 
defects in NK cell activity, macrophage function, complement activity, and dendritic cell 
function (136). The immunodeficiency of NSG mice means they lack the ability to reject 
foreign tissue (136), making them strong candidates for transplantation (136). Irradia-
tion was given to further deplete recipient bone marrow cells. Each NSG recipient mouse 
received 1 x 106 cells via tail vain injection. In separate experiments, recipient mice 
received either spleen cells from Sfpi1BN/BN mice, or cultured BN cells (cell line derived 
from Sfpi1BN/BN fetal liver progenitors, as previously described (102)).
Spleens were removed from 3-week-old, Sfpi1BN/BN neonates, homogenized, and 
subject to ACK (Ammonium-Chloride-Potassium) lysing buffer to remove erythrocytes. 
Spleen cells (splenocytes) were then washed three times in phosphate-buffered saline 
(PBS) (Lonza, Walkersville, MD). 1 x 106 splenocytes were resuspended in 500-700 μl of 
PBS and kept on ice in preparation for transplant. 
Cultured BN cells were washed three times in PBS. 1 x 106 BN cells were resus-
pended in 500-700 μl of PBS and kept on ice in preparation for transplant.
Post transplantation, mice were monitored for symptoms of disease, specifically 
laboured breathing and scruffy appearance.  When it appeared that the mouse was likely 
to die within 1-2 days, the mouse was euthanized via CO2 overdose. Following euthana-
sia, recipient spleens were analyzed via flow cytometry.
2.10 Flow Cytometry
Single-cell suspensions from spleens of recipient mice were analyzed by flow 
cytometry, as well as single-cell suspensions of cultured BN cells. Single-cell suspen-
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sions were washed in PBS containing 0.5 M EDTA (pH 8.0) and 0.5 % BSA prior to flow 
cytometry analysis. Cells were analyzed on a FACSCalibur (BD, Franklin Lakes, NJ). 
Antibodies directly conjugated to phycoerythrin (PE), fluorescein isothiocyanate (FITC), 
or peridinin-chlorophyll protein with cyanine dye (PerCP-Cy5.5) against the following 
markers were used: Mac-1/CD11b (M1/70), c-Kit/CD117 (2B8), FcγRII/III/CD32/CD16 
(2.4G2), B4/CD19 (1D3), Ki-67 (MKI67). For Gr-1/Ly-6C (8C5) the primary antibody 
was conjugated to biotin and detected using streptavidin-PE secondary antibody. Analysis 
was performed using FlowJo version 9.3.2 (Ashland, OR) according to standard proto-
cols. Gates on viable cells were set according to forward and side light scatter, as well as 
the exclusion of propidium iodide staining. Fluorescence activated cell sorting (FACS) 
was performed for transduced BN cells at the London Regional Flow Cytometry Facility 
(Robarts Research Institute) (London, Ontario, Canada) using a FACSAria III flow cy-
tometer using the blue laser (488 nm) for green fluorescent protein (GFP) positive cells.
2.11 Statistical Analysis
Statistical significance was determined by unpaired, two-tailed Student’s t-test or 
one-way ANOVA and Tukey’s Multiple Comparison Test using GraphPad Prism v.6. Dif-
ferences were considered significant with a p-value <0.05.
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CHAPTER 3: RESULTS
3.1 Sfpi1BN/BN spleen cells do not propagate in culture
We have previously shown that Sfpi1BN/BN fetal liver cells can be cultured indefi-
nitely in GM-CSF, whereas Sfpi1BN/+ and Sfpi1+/+ fetal liver cells cannot (unpublished 
data). We therefore wanted to establish whether the same would be true of Sfpi1BN/BN 
spleen cells, compared to their Sfpi1BN/+ or Sfpi1+/+ counterparts.  In order to determine 
whether Sfpi1BN/BN spleen cells could be propagated in culture, Sfpi1BN/BN spleen cells were 
obtained from a neonatal Sfpi1BN/BN mouse (as well as a Sfpi1BN/+ littermate) and 10, 000, 
000 cells from each mouse were placed into 10 ml of media containing the growth fac-
tor GM-CSF (1 ng/ml). Cells were passaged every 2-3 days and viable cell counts were 
recorded at each passage. At the first passage, the number of both Sfpi1BN/BN and Sfpi1BN/+ 
spleen cells had dropped dramatically to just over 1, 000, 000 cells (Figure 3.1). By the 
second passage, viable cell counts decreased further to ~500, 000, and a little over 300, 
000 at the third passage for both Sfpi1BN/BN and Sfpi1BN/+ spleen cells (Figure 3.1). The 
experiment was repeated three times and two of the three times all spleen cells from both 
the Sfpi1BN/BN and Sfpi1BN/+ were dead by the fourth passage (Figure 3.1). In one of the ex-
periments, the spleen cells from the Sfpi1BN/BN mouse, but not the heterozygote littermate, 
were able to grow past the fourth passage (up to passage number eight) but cell counts 
remained extremely low (data not shown). This experiment showed that Sfpi1BN/BN spleen 
cells cannot be cultured, and thus colony forming assays could not be performed using 
these cells.
3.2 The effect of G-CSF on BN cell differentiation and growth
As mentioned, our laboratory has created a novel hypomorphic allele of Sfpi1 
termed BN, which produces PU.1 at 20% of wild-type levels (102). Sfpi1+/BN mice were 
mated to breed Sfpi1BN/BN neonates. We have also generated a cultured cell line from 
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Figure 3.1 Sfpi1BN/BN spleen cells do not propagate in culture. Spleen cells were ob-
tained from a neonatal  Sfpi1BN/BN mouse (as well as Sfpi1+/BN littermate) and 10 000 000 
cells from each mouse were placed into culture containing GM-CSF (1 ng/ml). Cells were 
passaged and counted every 2 -3 days until all cells were dead and experiment was ter-
minated. Cell counts were recorded at start of experiment and each passage. Black bars 
represent spleen cells from Sfpi1BN/BN mouse.  Results are presented as the mean + SD of 
three experiments (n=3). 
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Sfpi1BN/BN mice. The cell line is derived from Sfpi1BN/BN fetal liver progenitors (102). The 
cell line is referred to as BN (102). BN cells are cultured in the growth factor, GM-CSF, 
as they are a GM-CSF dependent cell line (unpublished data). They have also been shown 
to thrive in interleukin-3 (IL-3) (102).
Previous work by Panopoulos et al. showed that the cytokine G-CSF is capable of 
stimulating a pathway dependent on Stat3, a major G-CSF responsive signaling protein 
(137), that may result in the differentiation of myeloid cells. As a result, we attempted to 
assess the differentiation potential of cultured BN cells as a result of G-CSF by culturing 
them with or without G-CSF (10 ng/ml). In order to determine whether or not differentia-
tion had occurred as a result of G-CSF treatment, we analyzed expression of the myeloid-
specific, terminal differentiation cell surface marker CD11b (107). We also analyzed 
expression of the cell surface marker, c-Kit, which is a marker of myeloid progenitor cells 
(12). We hypothesized that if BN cells were able to differentiate as a result of exposure to 
G-CSF, CD11b would be up-regulated in BN cells grown with G-CSF compared to those 
grown without G-CSF. Furthermore, BN cells grown in G-CSF that had differentiated 
would down-regulate c-Kit. We cultured 4, 000, 000 BN cells in one of the following cy-
tokine conditions: GM-CSF (10 pg/ml) alone, or GM-CSF (10 pg/ml) and G-CSF (10 ng/
ml), and analyzed for CD11b and c-Kit expression via flow cytometry after 3 days of cul-
ture. Our results showed that there was no difference in either CD11b or c-Kit expression 
between BN cells grown with or without G-CSF (Figure 3.2). There was no significant 
difference (p = 0.5537) between mean fluorescence for CD11b of BN cells grown without 
G-CSF (black bar, Figure 3.2 B) versus those grown with G-CSF (grey bar, Figure 3.2 B). 
There was also no significant difference (p = 0.9346) between mean fluorescence for c-
Kit of BN cells grown without G-CSF (black bar, Figure 3.2 D) versus those grown with 
G-CSF (grey bar, Figure 3.2 D). Therefore, our data suggests that G-CSF does not induce 
differentiation of BN cells based on the expression of the terminal differentiation marker 
CD11b, and the immature, progenitor marker, c-Kit.
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Figure 3.2 BN cells cultured in G-CSF do not up-regulate expression of CD11b or 
down-regulate expression of c-Kit. Cultured BN cells were grown in media containing 
either GM-CSF (10 pg/ml) alone, or a combination of GM-CSF (10 pg/ml) and G-CSF 
(10 ng/ml). Following 3 days of culture, cells were analyzed by flow cytometry for ex-
pression of cell surface markers. (A) Histogram shows expression of CD11b, a myeloid-
specific cell surface marker, for BN cells grown in GM-CSF alone (black), or a combi-
nation of GM-CSF and G-CSF (grey).  (B) Bar graph shows the mean fluorescence of 
CD11b expression for BN cells grown in GM-CSF alone (black bar), or BN cells grown 
in GM-CSF and G-CSF (grey bar). (C) Histogram shows expression of c-Kit, a cell sur-
face marker of myeloid progenitor cells, for BN cells grown in GM-CSF alone (black), 
or a combination of GM-CSF and G-CSF (grey). (D) Bar graph shows the mean fluores-
cence of c-kit expression for BN cells grown in GM-CSF alone (black bar), or BN cells 
grown in GM-CSF and G-CSF (grey bar). Histograms are representative images from one 
of three experiments (n=3), while bar graphs are presented as the mean + SD of the three 
experiments. 
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We next investigated whether or not BN cells, a GM-CSF dependent cell line 
(unpublished data), could also be grown in G-CSF. We cultured 100 000 BN cells in one 
of the following cytokine conditions: GM-CSF (1 ng/ml) alone, GM-CSF (1 ng/ml) and 
G-CSF (10 ng/ml), or G-CSF (10 ng/ml) alone, and measured their proliferation after 4 
days of culture. Cultured BN cells grown in GM-CSF alone or the combination of GM-
CSF and G-CSF grew equally well; both showed over 20-fold expansion (Figure 3.3). 
Nonetheless, there was no significant difference (p = 0.8142) between BN cells grown 
in GM-CSF alone or the combination of GM-CSF and G-CSF. In contrast, cells grown 
in G-CSF only were unable to proliferate (Figure 3.3). BN cells grown in GM-CSF only 
proliferated significantly more than BN cells grown in G-CSF only (p = <0.0001) (Figure 
3.3, ****). BN cells grown in the combination of GM-CSF and G-CSF also prolifer-
ated significantly more than BN cells grown in G-CSF only (p = 0.0170) (Figure 3.3, *). 
Therefore, our data illustrates that BN cells are not responsive to G-CSF. G-CSF did not 
permit growth when used exclusively, but could be used in combination with GM-CSF. 
However, the combination of growth factors did not increase proliferation compared to 
GM-CSF used independently.
3.3 Co-culture with retroviral producing cells does not allow effective restoration of 
PU.1 expression
In order to test the hypothesis that restoration of PU.1 expression in cultured BN 
cells would result in cell cycle exit, reduced proliferation and ultimately differentiation, 
cultured BN cells were co-cultured with mitomycin C treated GP + E86 packaging cells, 
a retroviral producing cell line (Figure 3.4A). GP +E86 packaging cells were treated with 
mitomycin C to prevent proliferation. BN cells were grown in the presence of GP + E86 
cells producing a previously constructed retrovirus (termed MIG-PU.1) that expresses 
a 3X-FLAG tagged PU.1 gene, as well as the marker GFP. As a control, BN cells were 
grown in the presence of GP + E86 cells producing an empty retroviral vector, (termed 
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Figure 3.3 The cytokine G-CSF does not enable nor inhibit growth of cultured BN 
cells. Cultured BN cells were grown in media containing either GM-CSF (1ng/ml) alone 
(hatched bar), a combination of GM-CSF (1 ng/ml) and G-CSF (10 ng/ml) (black bar), or 
G-CSF (10 ng/ml) alone (white bar). 100 000 cells were plated in each cytokine condition 
and cell counts were taken following 4 days of culture. Results are presented as the mean 
+ SD of one experiment (n=1) performed in triplicate. Significant differences are indi-
cated with asterisk (*).
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MIGR1) where PU.1 was not introduced.  The MIGR1 retroviral vector still expresses 
GFP. BN cells were cultured in direct contact with the retrovirus producing cells for 3 
days before they were transferred to a second co-culture with fresh retroviral packaging 
cells. Following the two rounds of retroviral transduction, we attempted to select for BN 
cells where PU.1 expression had been restored, by culturing cells in media containing 
GM-CSF, as well as M-CSF. While BN cells are known to express the GM-CSF recep-
tor, they do not express the M-CSF receptor. However, PU.1 activates expression of the 
M-CSF receptor (104) and theoretically, BN cells that successfully take up the MIGPU.1 
retrovirus should be able to respond to stimulation with M-CSF and grow in the presence 
of M-CSF while uninfected cells should not (Figure 3.4A). As mentioned, MIG retrovi-
ruses are tagged with GFP and retrovirally infected BN cells will be GFP positive. The 
highest transduction frequencies achieved using the co-culture method are illustrated in 
Figure 3.4B. While transduction frequencies were able to reach a relatively high level, 
this did not occur consistently. Furthermore, infected BN cells that were recovered after 
selection in M-CSF were mostly dead based on trypan blue cell counting. 
3.4 Inducible expression system enables restoration of PU.1, up-regulation of PU.1 
target genes and differentiation
In order to assess the effect of PU.1 restoration on BN cells before cell death, we 
developed a technique in which we could systematically induce PU.1 expression. The 
system exploited two separate retroviral vectors, termed the regulator and the response. 
The regulator vector encoded the Tet-On 3G transactivator protein, as well as GFP (Fig-
ure 3.5A). The response vector contained the gene encoding PU.1 under the control of 
a TRE3G promoter (PTRE3GV), as well as a puromycin resistance gene (Figure 3.5A). 
In the presence of doxycycline (Dox), Tet-On 3G binds specifically to PTRE3GV and 
activates transcription of downstream PU.1. In order to set up the system, cultured BN 
cells were infected with the regulator and response retroviruses simultaneously (Figure 
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Figure 3.4 Infection of BN cells via co-culture. (A) Schematic of co-culture method 
used to restore PU.1 expression in BN cells. BN cells, a GM-CSF dependent cell line, 
were cultured in the presence of mitomycin C treated, GP + E86 packaging cells produc-
ing either MIGR1 or MIGPU.1 retrovirus for 3 days, after which they were transferred 
into a second culture of fresh GP + E86 packaging cells. Following the second 3-day co-
culture, BN cells were transferred to media containing GM-CSF (10 pg/ml) and M-CSF 
(10 ng/ml) to select for infected cells. (B) Highest infection frequencies reached for BN 
cells infected with either MIGR1 (left panel) or MIGPU.1 (right panel) retrovirus using 
the co-culture technique. Open histograms show expression of green fluorescent protein 
(GFP).  Black histograms represent negative (uninfected) cells. Histograms are represen-
tative images from one of three experiments (n=3); the percentage of infected BN cells 
+/- SD of the three experiments is listed in the top right hand corner. 
46
100 101 10 2 10 3 10 4
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
MIGR1 MIG-PU.1
GFP
# 
Ce
lls
48.8 +/- 17.0% 31.2 +/- 15.4%
# 
Ce
lls
BN cells
IMDM + GM-CSF GP + E86 retroviral producing
packaging cells
BN cells
B
IMDM + GM-CSF + M-CSF
BN cells
A
47
Figure 3.5 Construction of inducible system used to restore expression of PU.1. (A) 
Two separate retroviral vectors were used in the inducible system. The regulator vector 
contains the Tet-On 3G transactivator protein, which in the presence of doxycycline is 
able to bind and activate expression of the PTRE3G inducible promoter. The PTRE3G 
promoter controls expression of PU.1 and is located in the pRetroX-TRE3G response 
vector. A selectable marker was also part of each vector. The regulator vector contains the 
gene encoding GFP and the response vector contains a puromycin resistance gene. (B) 
Cultured BN cells were infected with both regulator and response retroviral vector super-
natants simultaneously via spin infection. Following infection, BN cells were cultured 
in media containing puromycin to select for BN cells that had successfully taken up the 
response vector containing the puromycin resistant gene.  Puromycin resistant cells were 
then screened for GFP positivity using a combination of cloning and cell sorting to select 
for cells that also contained the regulator vector. Finally doxycycline was added at a 
concentration of 1000 ng/ml to BN cells infected with both regulator and response retro-
viruses, effectively turning on PU.1 expression.
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3.5B). Infected cells were selected by growth in the presence of puromycin (Figure 3.6A). 
Puromycin resistant cells were also screened for GFP positivity by flow cytometry. FACS 
for GFP expression was conducted to enrich a population of purified GFP positive cells 
(Figure 3.6B,D). The presence of the Tet-On 3G protein was confirmed in selected cells 
by immunoblot using the TetR monoclonal antibody (Figure 3.6C). GFP positive, puro-
mycin resistant BN cells were then grown in culture with doxycycline (1000 ng/ml) to 
induce PU.1 expression (Figure 3.5B). BN cells successfully infected with both retroviral 
vectors expressed high levels of PU.1, when cultured in the presence of doxycycline, as 
confirmed by immunoblot (Figure 3.7A). Finally, CD11b expression was analyzed by 
flow cytometry in dox induced versus non-induced cells. CD11b is directly activated by 
PU.1 (107) and therefore PU.1 reintroduction should result in an up-regulation of CD11b 
expression. As well, CD11b is a cell surface marker, specific to mature myeloid cells 
(107) and indicates differentiation. As expected, CD11b was up-regulated in dox induced 
BN cells compared to non-induced cells (Figure 3.7B). Thus, following PU.1 restoration, 
BN cells showed signs of differentiation by expressing a terminal differentiation marker, 
CD11b.
3.5 Restoration of PU.1 expression in cultured BN cells results in reduced 
proliferation and cell cycle exit at the G0/G1 phase
Once PU.1 restoration was established, we assessed the biological effect of 
restoration in cultured BN cells. In order to address the hypothesis that PU.1 restoration 
will allow immature progenitors to exit the cell cycle and differentiate, we looked at the 
ability of BN cells to grow over 4 days of culture, in the presence of various concentra-
tions of doxycycline. At a concentration as low as 100 ng/ml, induction resulted in a 
decrease in cell proliferation, compared to untreated control (Figure 3.8). The cell count 
was significantly lower (p < 0.05) (Figure 3.8, *) for regulator and response infected BN 
cells grown in the presence of doxycycline (100 ng/ml) than infected BN cells grown in 
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Figure 3.6 Selection of BN cells infected with both regulator and response retroviral 
supernatants. (A) Selection of BN cells successfully infected with the response vector. 
(+) indicates retroviral infected BN cells. (-) indicates uninfected BN cells. Cells able to 
grow in the presence of puromycin contain the response vector (n=1). (B) Selection of 
BN cells successfully infected with the regulator vector (n=1). GFP positive cells indicate 
the presence of the regulator vector. The histogram shows expression of GFP.  Red rep-
resents negative (uninfected) BN cells.  Blue represents regulator and response infected 
BN cells. (C) An immunoblot was conducted to confirm the presence of the Tet-On 3G 
transactivator protein in GFP positive cells using the TetR monoclonal antibody (n=1). 
b-actin served as a control.  (D) Using fluorescence microscopy, an image was taken of 
puromycin resistant, GFP+ve BN cells (n=1). 
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Figure 3.7 Restoration of PU.1 expression and up-regulation of CD11b following 
induction. (A) An immunoblot was conducted using anti-PU.1 antibody to demonstrate 
PU.1 restoration following induction with doxycycline (1000 ng/ml) (n=1). An anti-actin 
antibody was used as a control. (B) Flow cytometry on induced BN cells, 5 days follow-
ing doxycycline (1000 ng/ml) induction. The histogram shows expression of CD11b, a 
direct target of PU.1. Open histogram represents non-induced BN cells while filled black 
histogram represents CD11b expression after doxycycline treatment of BN cells. Histo-
gram is a representative image from one of three experiments (n=3).
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Figure 3.8 Restoration of PU.1 expression following induction by doxycycline re-
sults in a block in proliferation. Cell growth of retrovirally infected BN cells at various 
concentrations of doxycycline (black bars). Uninfected BN cells (white bars) were grown 
in the presence of doxycycline (1000 ng/ml) as a control for possible growth inhibition by 
doxycycline.  Results are presented as the mean and SD of three experiments (n=3). Cell 
growth at each different doxycycline concentration of retroviral infected BN cells was 
compared to cell growth of infected BN cells grown in the absence of doxycycline, fol-
lowing 4 days of culture. Significant differences are indicated with asterisk (*).
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the absence of doxycycline (Figure 3.8). There was a gradual reduction in cell counts as 
the concentration of doxycycline increased (Figure 3.8). To eliminate the possibility that 
the doxycycline was toxic to the cells, we grew uninfected BN cells in the presence of a 
high concentration of doxycycline (1000 ng/ml) (Figure 3.8). The cell counts were not 
significantly different (p > 0.05) between uninfected BN cells grown in the presence of 
doxycycline (1000 ng/ml) and those grown in the absence of doxycycline (Figure 3.8), 
which indicated that the concentration of doxycycline being used for induction was not 
toxic. These results suggest that increased PU.1 expression might be promoting cell cycle 
exit or apoptosis.
The reduction in proliferation following PU.1 restoration prompted investigation 
into the cell cycle. Cell cycle analysis was conducted using BrdU and 7-AAD to identify 
cells actively synthesizing DNA during the different stages of the cell cycle (G0/G1, S, or 
G2/M). This technique permits quantification of the frequency of cells in each phase of 
the cell cycle. Doxycycline induced cells were mostly apoptotic (47.5%) (Figure 3.9B). 
Importantly, more non-induced cells were in S phase (52.5%), compared to doxycycline 
induced cells (25.2%) (Figure 3.9C,D), implying a block in the G1 to S phase transition 
following PU.1 restoration. These results suggest that PU.1 restoration results in cell 
cycle exit, specifically at the G1 to S phase transition.
3.6 PU.1 regulates the cell cycle by repressing E2F1
Previous work in our lab determined an inverse relationship between PU.1 ex-
pression and the cell cycle regulator E2F1 (unpublished data). In Sfpi1BN/BN mouse spleen 
cells, where PU.1 levels were reduced, E2F1 levels were increased compared to Sfpi1BN/+ 
mice (unpublished data). Our cell cycle analysis results support this finding as E2F1 
functions in the transition from G1 to S phase (126). As a result, we hypothesized that 
PU.1 regulates the cell cycle via repression of E2F1. To test this hypothesis, we exam-
ined whether E2f1 transcript and E2F1 protein was reduced following PU.1 restoration in 
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Figure 3.9 PU.1 restoration blocks G1 to S phase transition. Cell cycle analysis was 
conducted to determine the position of cells within the cell cycle. Cycling of non-induced 
BN cells (white) was compared to doxycycline induced BN cells (black). (A) Gating 
strategy used (gating of non-induced cells is shown); G1 represents apoptotic cells; G2 
represents live cells. (B) Quantification of the percentage of apoptotic (G1) and live (G2) 
cells under the two conditions (non-induced (white) compared to doxycycline induced 
(black) BN cells). (C) BrdU incorporation was measured by flow cytometry on G2 cells  
in non-induced BN cells (white) and doxycycline induced BN cells (black). (D) Quantifi-
cation of the percentage of cells in S phase as indicated by BrdU incorporation for non-
induced BN cells (white) and doxycycline induced BN cells (black). 
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cultured BN cells. Reverse transcriptase qPCR (RT-qPCR) analysis demonstrated a 3.1 
fold reduction in E2f1 transcripts in BN cells where PU.1 expression had been restored 
(Figure 3.10). Western blot analysis confirmed a substantial reduction in E2F1 protein in 
doxycycline induced BN cells compared to non-induced cells (Figure 3.11). In conclu-
sion, our results establish PU.1 as a repressor of E2f1 gene expression.
3.7 The spleens of Sfpi1BN/BN mice contain a population of highly proliferative, 
myeloid cells
As described in the introduction, our laboratory has developed a mouse model in 
which mice homozygous for the Sfpi1 BN allele produce PU.1 at 20% of wild-type levels 
(102). Mice homozygous for Sfpi1 allele (Sfpi1BN/BN mice) also demonstrated hyperpro-
liferation of immature myeloid cells in the bone marrow, spleen and other tissues (102). 
To demonstrate increased proliferation in the spleens of Sfpi1BN/BN mice, flow cytometric 
analysis was performed for the nuclear protein Ki-67, as well as the myeloid specific 
cell surface marker CD11b. Ki-67 is highly expressed in proliferative cells; it is present 
during active cell cycle but absent from resting cells (138). Flow cytometric analysis was 
performed using single-cell suspensions from the spleens of 21-day Sfpi1BN/BN and Sfpi1+/+ 
mice. There was an up-regulation of both CD11b and Ki-67 in Sfpi1BN/BN spleen cells 
compared to Sfpi1+/+ mice (Figure 3.12). In the representative images, the mean fluores-
cence intensity of Ki-67 expression in Sfpi1BN/BN spleen cells was 752 compared to 459 in 
Sfpi1+/+  spleen cells (Figure 3.12). Flow cytometric analysis of Sfpi1BN/BN spleens demon-
strated an increase in the frequency of myeloid, proliferative cells compared to littermate 
control, as indicated by CD11b and Ki-67 expression, respectively (Figure 3.12). These 
results suggest that myeloid proliferation is increased in the spleens of Sfpi1BN/BN mice.
3.8 Transplantation studies
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Figure 3.10 E2f1 is down-regulated upon induction of PU.1 with doxycycline. RT-
qPCR was performed to determine relative frequencies of E2f1 transcripts in doxycycline 
induced BN cells compared to non-induced BN cells. RNA was prepared from retroviral 
infected BN cells cultured in the presence of doxycycline (1000 ng/ml) and absence of 
doxycycline. Fold change is shown in reference to the housekeeping gene beta-2-mi-
croglobuliin (B2M). Results are presented as the mean + SD of three experiments (n=3) 
performed in triplicate. Significant differences are indicated with asterisk (*).
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Figure 3.11 E2F1 protein level is decreased upon induction of PU.1 with doxycycline. 
An immunoblot was conducted using anti-E2F1 antibody to demonstrate E2F1 repression 
by PU.1 following PU.1 restoration with doxycycline (1000 ng/ml) (n=1). As a control an 
immunoblot was conducted using anti-actin antibody.
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Figure 3.12 Sfpi1BN/BN myeloid cells are increased in frequency in vivo. The spleens of 
21-day Sfpi1BN/BN mice (right panels) contain a proliferative (Ki-67high), myeloid (CD11b+) 
population that is increased compared to wild-type (wt) littermates (left panels). Flow-cy-
tometric analysis of CD11b, a myeloid-specific cell surface marker, and Ki-67, a nuclear 
protein highly expressed in proliferative cells, was performed using single-cell suspen-
sions from the spleens of 21-day Sfpi1BN/BN or Sfpi1+/+ mice. Flow-cytometric analysis of 
single-cell suspensions from the spleens of 21-day Sfpi1BN/BN mice (right panels) demon-
strates a larger population of CD11b+ myeloid cells (top) as well as an upregulation of 
Ki-67 (bottom), in comparison to Sfpi1+/+ mice (left panels). Histograms are representa-
tive images from one of two experiments (n=2); the percentage of CD11b +/- SD cells of 
the two experiments is listed in the top two plots. The mean fluorescence (MF) of Ki-67 
expression of the representative image is listed in the bottom two plots.
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In order to determine whether reduced expression of PU.1 in Sfpi1BN/BN myeloid 
cells is sufficient to cause the development of AML in mice, transplantation studies were 
conducted. NSG mice were each injected with either 1 x 106 splenocytes from Sfpi1BN/
BN mice, or cultured BN cells. Recipient mice were monitored for symptoms of AML and 
when a mouse showed laboured breathing and scruffy appearance (likely to die within 
1-2 days), the mouse was euthanized and the morphology of the spleen was analyzed, 
as highly enlarged spleens are characteristic of leukemic mice (Figure 3.13). Single cell 
suspensions were prepared from the spleens of recipient mice and analyzed for engraft-
ment and myeloid cell composition by flow cytometry. In order to conclude that mice 
have become sick due to AML, a population of immature, myeloid cells must be present. 
To verify the composition of cells, CD11b and c-Kit were used. As previously mentioned, 
c-Kit is expressed at high levels in immature progenitors (12), while CD11b is a cell 
surface marker of the myeloid lineage (107). Other myeloid cell surface markers, such as 
Gr-1 and FcγRII/III were also analysed. CD19, a B cell-specific marker (139) was also 
examined to exclude the possibility of a B cell leukemia. The cell surface marker CD45.2 
was used for donor cells from Sfpi1BN/BN mice to indicate whether or not engraftment took 
place. CD45.2 is expressed on the surface of donor cells (Figure 3.14A) but not in the 
recipient NSG mice; whereas NSG mice express the CD45.1 cell surface marker (Figure 
3.14A). Because the cultured BN cell line did not express CD45.2 (Figure 3.16A), we 
generated a line of GFP +ve BN cells (Figure 3.16B), used to determine the origin of the 
cell population present in recipient mice for transplant work with the cultured BN cells. 
NSG mice transplanted with Sfpi1BN/BN spleen cells (n = 6) had a median survival 
of 50 days (Figure 3.13A), while NSG mice transplanted with cultured BN cells (n = 8) 
had a median survival of 90.5 days (Figure 3.13B). A large population of immature (c-
Kit+), myeloid (CD11b+, CD19-) cells was present in the spleens of NSG mice injected 
with Sfpi1BN/BN spleen cells (Figure 3.15 A, B, C, middle panels) or BN cells (Figure 3.15 
A, B, C, right panels), compared to wild-type spleens (Figure 3.15 A, B, C, left panels). 
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Figure 3.13 NOD/SCID/γc mice transplanted with Sfpi1BN/BN splenocytes or 
cultured BN cells become sick and require euthanasia after transplantation. (A) 
Survival of NOD/SCID/γc (NSG) mice (n=6) injected with splenocytes from Sfpi1BN/BN.  
The median survival was 50 days. (B) Survival of NSG mice (n=8) injected with cul-
tured BN cells. The median survival was 90.5 days.
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Figure 3.14 NOD/SCID/γc mice transplanted with Sfpi1BN/BN splenocytes or cultured 
BN cells contain a donor-derived population of cells.
Flow cytometric analysis was conducted using single cell suspensions from the spleens 
of wild type C57/Bl6 mice, wild type NOD/SCID/γc (NSG) mice, NSG recipient mice 
transplanted with Sfpi1BN/BN splenocytes, or NSG recipient mice transplanted with 
cultured BN cells. Sfpi1BN/BN splenocytes were isolated from C57/Bl6 Sfpi1BN/BN mice. 
Sfpi1BN/BN splenocytes and cultured BN cells were isolated and transplanted by tail vein 
injection into sublethally irradiated NSG recipients.  Recipient mice were injected with 
1 x 106 cells/recipient mouse.
(A) Donor mice (C57/Bl6) express CD45.2 (grey histograms) while recipient mice 
(NSG) express CD45.1 (black histograms). Histograms are representative images from 
one of three experiments (n=3). (B) The dot plots show expression of the cell surface 
markers CD45.1 and CD45.2. Cultured BN cells did not express either CD45 marker. 
Engraftment of Sfpi1BN/BN CD45.2+ donor cells in NSG CD45.1+ recipient mice is shown 
in the middle dot blot. Engrafted cultured BN cells are CD45.1- and CD45.2- (right dot 
plot).
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Figure 3.15 NOD/SCID/γc mice transplanted with Sfpi1BN/BN splenocytes or 
cultured BN cells contain a large population of immature (c-Kit+ve), myeloid 
(CD11b+ve, FcγRII/III+ve, Gr-1+ve, CD19-ve) cells, indicative of AML. Flow cytomet-
ric analysis was conducted using single cell suspensions from the spleens of WT C57/
Bl6 mice (left panels), NOD/SCID/γc (NSG) recipient mice transplanted with Sfpi1BN/
BN splenocytes (middle panels), or NSG recipient mice transplanted with cultured BN 
cells (right panels). Sfpi1BN/BN splenocytes were isolated from C57/Bl6 Sfpi1BN/BN mice. 
Sfpi1BN/BN splenocytes and cultured BN cells were isolated and transplanted by tail 
vein injection into sublethally irradiated NSG recipients.  Recipient mice were injected 
with 1 x 106 cells/recipient mouse. Histograms show expression of c-Kit (A), which is 
a cell surface marker of immaturity, CD11b (B) a myeloid-specific cell surface marker, 
and CD19, a B cell-specific marker (C). Histograms also show expression of FcγRII/
III (D) and Gr-1 (E), both myeloid cell surface markers. Open histograms represent the 
negative (unstained) control. Histogram gating strategies are shown in Figure 3.14 on 
the CD45.2+ population (wt C57/Bl6 mice and NSG recipient mice transplanted with 
Sfpi1BN/BN splenocytes) and CD45.1- population (NSG recipient mice transplanted with 
cultured BN cells). All histograms are representative images.
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Spleen cells of NSG transplanted with either Sfpi1BN/BN spleen cells or BN cells also ex-
pressed high levels of FcγRII/III and Gr-1, compared to wild-type spleens (Figure 3.15 D, 
E). Engraftment was demonstrated in NSG mice transplanted with Sfpi1BN/BN spleen cells 
by the CD45.2 expression of cells present in recipient spleens (Figure 3.14 B middle dot 
plot). Engraftment was suggested in NSG mice transplanted with cultured BN cells by the 
lack of CD45.1+ cells (Figure 3.14 B right dot plot). Engraftment was confirmed in NSG 
mice transplanted with GFP +ve BN cells by the population of cells expressing GFP in re-
cipient spleens (Figure 3.16C). Finally, upon euthanasia, recipient mice had significantly 
enlarged spleens (data not shown), a characteristic of AML. Taken together, these results 
suggest that NSG transplanted with Sfpi1BN/BN splenocytes or cultured BN cells become 
sick with disease resembling AML following transplantation.
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Figure 3.16 Generation of a GFP+ve BN cell line to use in transplantation studies. 
(A) Cultured BN cells did not express the CD45.2 cell surface marker (n=1). (B) Cul-
tured BN cells were made GFP+ve using a retroviral infection in order to identify donor 
cell population in transplantation studies (n=1). (C) Flow-cytometric analysis was con-
ducted using single-cell suspensions from the spleen of a NOD/SCID/γc (NSG) recipi-
ent mouse transplanted with cultured GFP+ve BN cells. The right panel shows a GFP+ve 
population present in a NSG recipient spleen, demonstrating engraftment (n=1). The 
left panel shows the spleen of a NSG injected with non-GFP+ve BN cells (n=1).
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CHAPTER 4: DISCUSSION 
4.1 Overview
The goal of this project was to determine the role of PU.1 in cell cycle regulation 
and the development of AML. We have shown that a reduction in PU.1 expression resulted 
in the development of AML in NOD/SCID/gc mice ~70 days after transplantation. Based 
on our in vitro results, we propose that the development of AML in these mice was likely 
due to lack of cell cycle exit and terminal differentiation, which corresponds to insufficient 
PU.1 levels. Our work demonstrated that restoration of PU.1 expression promotes cell 
cycle exit and permits terminal myeloid differentiation. Furthermore, we have elucidated 
the mechanism by which cell cycle exit is able to occur; recovered expression of PU.1 
resulted in repression of the potent cell cycle activator, E2F1. Taken together, these results 
provide strong evidence that PU.1 regulates the cell cycle through repression of E2F1, and 
insufficient E2F1 repression due to reduced levels of PU.1 expression results in the devel-
opment of AML.
4.2 Restoration of PU.1 expression results in decreased proliferation, increased 
differentiation, and cell cycle block in G1 to S phase transition
 While the phenotype of mice and cultured cells with reduced expression of PU.1 
have been previously characterized (47, 102), we sought to determine if the characteris-
tics of these mice and cells could be reversed upon PU.1 restoration.  In order to do this, 
we used a cell line, derived from the fetal liver cells of Sfpi1BN/BN mice (BN cells).  In or-
der to reintroduce PU.1, we employed a retrovirus encoding a PU.1 cDNA that was under 
the control of an inducible promoter. This strategy allowed us to precisely induce expres-
sion of PU.1 in the presence of doxycycline.  Upon induction with doxycycline, prolifera-
tion of BN cells decreased dramatically. Furthermore, BN cells in which PU.1 expression 
had been restored showed the progression of differentiation by expressing higher levels 
of the terminal differentiation marker CD11b. In summary, PU.1 restoration enabled cell 
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cycle exit, and induced cell differentiation, demonstrating that myeloid cell proliferation/
differentiation was strictly related to PU.1 levels, implying a role for PU.1 in cell cycle 
regulation.
To assess the role of PU.1 in cell cycle progression, we measured 5-bromode-
oxyuridine (BrdU) incorporation in combination with 7-amino-actinomycin D (7-AAD) 
staining in vitro. BrdU permits identification of cells that are actively synthesizing DNA 
while 7-AAD defines cell cycle stage (G0/1, S, or G2/M). We compared cell cycle stage 
in PU.1-deficient BN cells versus doxycycline induced BN cells, where PU.1 expression 
had been restored. BrdU/7-AAD staining revealed that PU.1-deficient BN cells, were 
actively cycling, as evidenced by an increased number of S stage cells. In contrast, doxy-
cycline induced cells had a large proportion of cells that were apoptotic. This experiment 
suggests that PU.1 inhibits the G1 to S phase transition, allowing cells to exit the cell 
cycle and differentiate. This concept is supported by the role PU.1 plays in terminal my-
elopoiesis. Several groups have shown that PU.1 levels increase during granulocytic and 
monocytic differentiation (47, 87-88, 140). When PU.1 levels are decreased to only 20% 
of wild-type levels, as in the BN cell line, cells are deregulated and remain in the cell 
cycle, unable to differentiate. This supports the phenotype of Sfpi1BN/BN mice that contain 
a highly proliferative, immature myeloid population (102). In summary, a role for PU.1 in 
cell cycle regulation is consistent with the necessity of PU.1 in terminal myeloid differen-
tiation. In addition, cells must properly exit the cell cycle for differentiation to occur. Due 
to the requirement of PU.1 for terminal myeloid differentiation, it makes sense that PU.1 
drives cell cycle exit. 
Our results are in agreement with the recently published data of Staber et al. that 
shows that PU.1 regulates proliferation in HSCs and that this effect is directly related to 
PU.1 levels (141). This group discovered that compared to wild-type mice, the prolifera-
tive fraction of HSCs was doubled and there was a substantial increase in S, G2, and M 
phase cells in mice expressing reduced levels of PU.1 (141). Importantly, restoration of 
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PU.1 levels reversed the S/G2/M fraction to normal levels (141).  Of note, the mouse 
knock-in model (PU.1 ki/ki) used in the work by Staber et al. (with targeted disruption 
within the -14 kb URE of murine PU.1) had unchanged PU.1 levels in the whole bone 
marrow compartment, but HSCs specifically demonstrated a PU.1 reduction to 40% of 
wild-type levels (141). Comparing this mouse model to that of Rosenbauer et al., which 
deleted the entire -14 kb enhancer region of PU.1, shows that the major phenotypic dif-
ference between the two strains appeared after the HSC stage, in the myeloid progeni-
tor compartment (47, 141). FACS profile for LIN-SCA+KIT+ HSCs was similar between 
strains; the myeloid progenitor profile was completely disturbed in Rosenbauer et al.’s 
URE-KO mice, whereas it appeared mostly normal in Staber et al. ‘s PU.1ki/ki mice (47, 
141). Furthermore, HSCs of URE KO mice progressed to leukemia whereas PU.1ki/ki mice 
did not (47, 141). In comparing our study to that of Staber et al., two important differenc-
es emerge between their model and our group; in the Staber et al. model PU.1 expression 
was reduced to 40% of wild-type levels (whereas ours was 20%) and reduced PU.1 ex-
pression was restricted to HSCs (while our reduction in PU.1 expression was applicable 
to all blood cell types, in which PU.1 is normally expressed) (102). Furthermore, Staber 
et al. investigated the long-term repopulation potential of HSCs (141), while we looked at 
the ability of reduced expression of PU.1 in myeloid progenitors to induce AML. As well, 
our mouse model developed leukemia, whereas theirs does not. This suggests that the 
reduction in PU.1 expression must be sufficiently low and widespread in order to block 
terminal differentiation, leading to the development of AML. 
4.3 E2F1 and its role in myeloid proliferation/differentiation
The finding that PU.1 restoration inhibited cell cycle progression, specifically at 
the G1 to S phase supported previous unpublished work in our lab that found an inverse 
correlation between PU.1 and E2F1 protein levels. E2F1 is a transcription factor that pro-
motes cell cycle progression and S-phase entry (123), by controlling the transcription of 
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genes required for cell division (126). Our results showed that following PU.1 restoration, 
both transcript and protein levels of E2F1 were down-regulated, indicating a repressive 
function for PU.1 on E2F1. In support of a role for E2F1 in the blood cell system, Zhu 
and colleagues have reported E2F1 as a regulator of hematopoietic cell proliferation and 
differentiation (142). Also, Amanullah et al. have demonstrated that E2F1 is a negative 
regulator of myeloid differentiation (143). They showed that deregulated expression of 
E2F1 blocked terminal myeloid differentiation, and promoted leukemogenicity in inter-
leukin-6 (IL-6) treated M1 cells in vivo (143). This finding nicely supports our evidence 
that reduced PU.1 levels and deregulated E2F1 levels (due to lack of PU.1 repression), 
result in the development of AML.
The strength of E2F1 as an activator of genes that are essential for cellular pro-
liferation is highlighted by the fact that E2F1 can override various growth-arrest signals, 
including TGF-β and the CKIs p16, p21, and p27, in some situations (144-146). This 
finding agrees with the role of E2F1 in cancer development, as deregulation of E2F1 has 
been largely implicated in human cancers (125, 130). Not unexpectedly, Rb function is 
compromised in most, if not all, of human cancers (130). Binding by Rb to E2F1 inhib-
its its transcriptional activation capacity (130); thus when Rb function is compromised, 
E2F1 is deregulated.
Other myeloid specific transcription factors have also been associated with cell 
cycle regulation both positively and negatively. The proto-oncogenes c-myb and c-
myc are positive regulators of cell cycle progression (34), while C/EBPα is a negative 
regulator and promotes cell-growth arrest by coordinating exit from the cell cycle. C/
EBPα has been shown to inhibit G1 to S phase transition in myeloid cells (147-148). Per-
haps the most important mechanism by which C/EBPα exerts its effect is by direct bind-
ing to E2F1 where the interaction between C/EBPα and E2F1enables growth inhibition in 
myeloid cells and was required for terminal differentiation (149-151). Due to the neces-
sity of both C/EBPα and PU.1 in myelopoieis, it would not be surprising if they both 
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shared the ability to promote cell cycle exit via repression of E2F1. 
Lastly, Gibbs et al. have shown that the protein product of the PU.1 target gene 
Egr-1 is able to abrogate the E2F1 block in terminal myeloid differentiation and conse-
quently suppress leukemia (134). In concordance with the fact that Egr-1 functions as a 
tumor suppressor when myeloid differentiation is blocked by E2F1, is the discovery that 
the human EGR-1 gene is frequently deleted or subject to monosomy in patients with 
myelodysplastic syndromes or AML (152-153). Thus, the tumour suppressor role of Egr-
1 may represent a strong candidate for differentiation treatment in certain types of leuke-
mias.
4.4 The mechanism by which PU.1 regulates the cell cycle
While we have successfully demonstrated PU.1 repression of E2f1 gene expres-
sion, the detailed mechanism by which PU.1 is regulating the expression remains unclear. 
PU.1 may directly bind the E2f1 promoter and repress transcription. Alternatively, the 
mechanism may be indirect, in which case PU.1 might activate another regulator which 
in turn blocks E2f1 transcription. 
Support for an indirect mechanism of repression comes from published evidence 
that PU.1 activates expression of a microRNA (miRNA), miR223, which then goes on 
to disrupt translation of E2F1 protein (154-156). MicroRNAs are noncoding RNA mol-
ecules that regulate the expression of target genes by binding imperfectly with regions in 
target messenger RNAs (mRNAs) (154). MicroRNAs control gene expression through 
both translational repression and degradation of target mRNAs (154). Recently it has 
been shown that the primary mechanism of action of miRNAs is translational inhibition 
and that this must occur before mRNA may be targeted for degradation (154). PU.1 has 
been shown to activate miR223 in the myeloid lineage (155). Pulikkan et al. have dem-
onstrated that miR223 targets and represses E2F1 during granulopoiesis (156). They went 
on to report that E2F1 protein was up-regulated in miR223 null mice and that miR223 
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blocks cell cycle progression in myeloid cells (156), providing substantial evidence for 
the claim that miR223 targets E2F1. Another group has confirmed the role of miR223 in 
terminal myeloid differentiation by showing that miR223 knockout mice display defec-
tive granulopoiesis (157). Furthermore, miR223 is down-regulated in different subtypes 
of AML (156) and miR223 is inactivated by the AML1-ETO fusion oncoprotein, which 
is present in many cases of AML (158). All this data supports a pathway by which, under 
normal conditions, PU.1 is expressed in myeloid progenitors, resulting in miR223 activa-
tion, and subsequent suppression of E2F1, cell cycle arrest at the G1 to S phase bound-
ary, and terminal myeloid differentiation. Conversely, when PU.1 is expressed at reduced 
levels, miR223 is not expressed, resulting in deregulated E2F1 protein levels, continual 
cell cycle progression of immature myeloid cells, and ultimately AML. 
Alternatively, one group has shown, through chromatin immunoprecipitation 
(ChIP), that there is a PU.1 binding site within the E2f1 promoter (159), suggesting a 
direct mechanism of repression. Staber et al. also went on to elucidate the mechanism 
through which PU.1 levels control the cell cycle. Using ChIP sequencing, they found 
that PU.1 positively regulated the transcription of cell-cycle inhibitors GFI1 and Cdkn1a 
(p21) and negatively regulated the transcription of the cell-cycle activators CDK1, E2F1, 
and Cdc25a through direct binding to their promoters and enhancers (141). 
In disagreement with the findings of Wontakal et al. and Staber et al., there is 
evidence that PU.1 does not function as a repressor (160). While Staber et al. demon-
strated that PU.1 binds cell cycle activator promoters and enhancers, they did not actually 
demonstrate repression as indicated by chromatin remodeling. Nevertheless, Staber et al. 
demonstrated increased cell cycle inhibitor activity with increasing amounts of PU.1, and 
decreased cell cycle activator activity (141). This finding suggests PU.1 is able to repress 
cell cycle activators, such as E2F1. As mentioned, PU.1 is normally associated with tran-
scriptional activation (160), and it is not known how PU.1 might act as a repressor.
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4.5 Reduced PU.1 levels result in AML
 In order to conclusively demonstrate that reduced expression of PU.1 is suffi-
cient to induce AML, transplantation studies were conducted. We injected 1 x 106 spleen 
cells from Sfpi1BN/BN mice into NSG recipient mice. All the recipient mice that received 
transplanted cells developed AML, and required euthanasia within 6-12 weeks. Recipient 
mice had splenomegaly due to an invasion of myeloblastic cells. We also injected 1 x 106 
cultured BN cells, into NSG recipients and found the same results as those obtained us-
ing the Sfpi1BN/BN splenocytes. Our results confirm what Dr. Tenen’s group found in 2004 
(Rosenbauer et al. 2004). Like our lab, Dr. Tenen’s group also characterized the pheno-
type of mice expressing reduced levels of PU.1, and performed transplantations. Impor-
tantly, while both mouse models displayed PU.1 expression at 20% of wild-type levels, 
the strategy used to reduce PU.1 expression was different. Dr. Tenen’s group deleted the 
entire -14 kb enhancer region of PU.1, while we targeted a coding region. As well, the 
length of time it took for mice to develop the disease, differed between studies. Mice 
homozygous for this ΔUREneo allele in Rosenbauer et al.’s work developed leukemia in 
as early as 3 weeks (47), however it took at least 6 weeks for our mice to become sick. 
Furthermore, Dr. Tenen’s group did not propose a mechanism behind the development of 
AML in their mice.  In another collaborative paper, it was mentioned that HSCs of URE 
KO mice progress to leukemia, and it is likely that dysregulated cell cycle regulators 
might be involved (141). Our work suggests that PU.1 repression of the cell cycle activa-
tor E2F1 is involved in cell cycle exit in the myeloid lineage.
Together, these results indicate that reduced expression of PU.1 is directly re-
sponsible for the development of AML and suggest that restoration of PU.1 expression in 
individuals with AML could be a therapeutic approach to restore normal myeloid differ-
entiation. The potency and relevance of E2F1 in cell cycle progression and cancer make 
it an extremely attractive target in the treatment of AML. The association between PU.1 
levels and E2F1 may be manipulated in the future treatment of cancer.
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4.6 Future directions
 This project provided insight into the role that PU.1 plays in cell cycle regula-
tion and the development of AML. Nonetheless, certain issues still need to be addressed. 
Primarily, the mechanism by which PU.1 regulates E2F1 must be determined. Several ex-
periments are proposed that could illustrate whether the mechanism is indirect or direct.
 In order to demonstrate indirect repression, manipulation of miR223 expression is 
required. Firstly, it must be established that reintroduction of PU.1 into cultured BN cells 
induces miR223 expression. Secondly, it needs to be determined whether transduction 
of cultured BN cells with miR223 using a retroviral vector, blocks, or at the very least, 
slows proliferation. As well, E2F1 protein levels should be assessed, following transduc-
tion with miR223. This is a key experiment because PU.1 expression is not being affect-
ed, but the block in proliferation would be attributed to miR223 translational repression 
of E2f1 mRNA, indicating an indirect mechanism of repression. However, miR223 may 
not be the only form of regulation, or may not play a role at all, and other mechanisms 
of indirect repression might exist. Exploring the role of miR223 would still be worth-
while, however, given the large amount of data supporting the indirect pathway involving 
miR223.
In order to demonstrate direct repression, ChIP sequencing is required to com-
pile predicted PU.1 binding sites within the regulatory regions of the E2f1 gene. Next, 
validation of the predicated PU.1 binding sites would be performed using standard ChIP. 
To confirm a repressive function, mutagenesis of the PU.1 binding site(s) within the 
E2f1 gene would be conducted, in AML cells. Mutagenesis could be accomplished using 
zinc-finger nucleases, which create double-strand breaks in target DNA sequences (161). 
If mutagenesis of the PU.1 binding site relieves repression of E2f1 transcriptional activ-
ity, the mechanism can be definitively stated as direct. As well, ChIP could be used to 
identify chromatin alterations, such as histone deacetylation or methylation, indicative of 
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transcriptional inactivation, within the E2f1 promoter, following PU.1 restoration.
  We will exploit the inducible system to further assess the effect of E2F1 on BN 
cell proliferation/differentiation. For example, following restoration of PU.1 expression 
in cultured BN cells, we could overexpress E2F1 to ascertain E2F1’s ability to block cell 
cycle arrest. Presumably, overexpression of E2F1 should prevent PU.1 from enabling 
cell cycle exit and differentiation of BN cells.  As well, knockdown of E2F1 using short 
hairpin RNA (shRNA), could be conducted to determine if a dose-dependent reduction in 
BN cell proliferation occurs. A significant reduction in E2F1 activity should slow BN cell 
growth.
 Finally, further elucidating mechanisms by which PU.1 regulates the cell cycle, 
aside from E2F1 repression, is necessary. This avenue would permit the discovery of 
more therapeutic targets in the treatment of AML. For example, verifying the cell cycle 
targets proposed by Staber et al. is one option.  
4.7 Summary and conclusions
 In this project we sought to explore the mechanism of how PU.1 works to regulate 
proliferation and differentiation of myeloid progenitors, and its role in the development 
of AML. In doing so, we hypothesized that reduced expression of PU.1 in Sfpi1BN/BN 
myeloid cells will result in the development of AML in transplanted mice due to deregu-
lation of the cell cycle, as well as reduced repression of E2F1. The evidence presented in 
this monograph supports our hypothesis. We successfully showed how PU.1 expression 
at 20% of wild-type levels is sufficient to induce AML in transplanted mice. Furthermore, 
we demonstrated that the effect of reduced PU.1 expression is deregulation of the cell 
cycle, due to lack of repression of E2F1. Whether PU.1 repression of E2F1 is direct or in-
direct remains to be confirmed. In conclusion we have shown that normal PU.1 levels are 
required to repress E2F1, enabling cell cycle exit and terminal differentiation of myeloid 
progenitors.
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